Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7879985,Half-life,Half-life of 8.82 hours and mean residence time of 12.18 hours were determined for MMI.,Pharmacokinetics and short-term clinicopathologic changes after intravenous administration of a high dose of methimazole in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879985/),h,8.82,724,DB00451,Levothyroxine
,7879985,mean residence time,Half-life of 8.82 hours and mean residence time of 12.18 hours were determined for MMI.,Pharmacokinetics and short-term clinicopathologic changes after intravenous administration of a high dose of methimazole in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879985/),h,12.18,725,DB00451,Levothyroxine
,2126579,half-life (t1/2),"In the euthyroid subjects, TRH blood levels had a half-life (t1/2) of 6.5 +/- 0.41 min, mean +/- SD, while t1/2 was 7.2 +/- 0.62 min in the hyperthyroid and t1/2 was 12 +/- 1.67 min (p less than 0.001) in the hypothyroid patients.",Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),min,6.5,951,DB00451,Levothyroxine
,2126579,t1/2,"In the euthyroid subjects, TRH blood levels had a half-life (t1/2) of 6.5 +/- 0.41 min, mean +/- SD, while t1/2 was 7.2 +/- 0.62 min in the hyperthyroid and t1/2 was 12 +/- 1.67 min (p less than 0.001) in the hypothyroid patients.",Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),min,7.2,952,DB00451,Levothyroxine
,2126579,t1/2,"In the euthyroid subjects, TRH blood levels had a half-life (t1/2) of 6.5 +/- 0.41 min, mean +/- SD, while t1/2 was 7.2 +/- 0.62 min in the hyperthyroid and t1/2 was 12 +/- 1.67 min (p less than 0.001) in the hypothyroid patients.",Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),min,12,953,DB00451,Levothyroxine
,2126579,metabolic clearance rate (MCR),The metabolic clearance rate (MCR) (82.2 +/- 15.3 liters/m2/day vs. 89.8 +/- 17.2) and the volume of distribution (Vd) (7.1 +/- 4.2 liters vs. 7.3 +/- 3.4) were approximately the same in the normal subjects and in the hyperthyroid group.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),[l] / [d·m2],82.2,954,DB00451,Levothyroxine
,2126579,metabolic clearance rate (MCR),The metabolic clearance rate (MCR) (82.2 +/- 15.3 liters/m2/day vs. 89.8 +/- 17.2) and the volume of distribution (Vd) (7.1 +/- 4.2 liters vs. 7.3 +/- 3.4) were approximately the same in the normal subjects and in the hyperthyroid group.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),,89.8,955,DB00451,Levothyroxine
,2126579,volume of distribution (Vd),The metabolic clearance rate (MCR) (82.2 +/- 15.3 liters/m2/day vs. 89.8 +/- 17.2) and the volume of distribution (Vd) (7.1 +/- 4.2 liters vs. 7.3 +/- 3.4) were approximately the same in the normal subjects and in the hyperthyroid group.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),l,7.1,956,DB00451,Levothyroxine
,2126579,volume of distribution (Vd),The metabolic clearance rate (MCR) (82.2 +/- 15.3 liters/m2/day vs. 89.8 +/- 17.2) and the volume of distribution (Vd) (7.1 +/- 4.2 liters vs. 7.3 +/- 3.4) were approximately the same in the normal subjects and in the hyperthyroid group.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),,7.3,957,DB00451,Levothyroxine
,2126579,MCR,MCR (66.2 +/- 15.3 liters/m2/day) and Vd (6.2 +/- 3.3 liters) were found to be lower in the hypothyroid patients.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),[l] / [d·m2],66.2,958,DB00451,Levothyroxine
,2126579,Vd,MCR (66.2 +/- 15.3 liters/m2/day) and Vd (6.2 +/- 3.3 liters) were found to be lower in the hypothyroid patients.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),l,6.2,959,DB00451,Levothyroxine
,2126579,elution profile,Blood samples taken 5 min after TRH i.v. injection had an elution profile of 9.94 ml.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),ml,9.94,960,DB00451,Levothyroxine
<,24449674,TSH2/TSH1 ratio,We observed a TSH reduction (TSH2/TSH1 ratio <1) in 36/53 (67.9%) of patients; the median TSH2/TSH1 ratio was 0.71 (IQR 0.37-1.14).,Comparison of TSH Levels with Liquid Formulation Versus Tablet Formulations of Levothyroxine in the Treatment of Adult Hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24449674/),,1,2789,DB00451,Levothyroxine
,24449674,TSH2/TSH1 ratio,We observed a TSH reduction (TSH2/TSH1 ratio <1) in 36/53 (67.9%) of patients; the median TSH2/TSH1 ratio was 0.71 (IQR 0.37-1.14).,Comparison of TSH Levels with Liquid Formulation Versus Tablet Formulations of Levothyroxine in the Treatment of Adult Hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24449674/),,0.71,2790,DB00451,Levothyroxine
,24449674,ratios,"The median TSH2/TSH1 ratios were 0.50 (IQR 0.31-0.72) and 0.85 (IQR 0.65-1.36) for patients with and without interfering factors, respectively.",Comparison of TSH Levels with Liquid Formulation Versus Tablet Formulations of Levothyroxine in the Treatment of Adult Hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24449674/),,0.50,2791,DB00451,Levothyroxine
,4095073,Plasma thyroxine concentrations,Plasma thyroxine concentrations were 7.38 +/- 45 (SE) ng/ml (n = 16) for the E2-treated quail and 3.38 +/- .53 ng/ml (n = 16) for the controls.,Increased clearance rate of plasma thyroxine accompanies estradiol-induced vitellogenesis in male Japanese quail. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095073/),[ng] / [ml],7.38,7027,DB00451,Levothyroxine
,4095073,Plasma thyroxine concentrations,Plasma thyroxine concentrations were 7.38 +/- 45 (SE) ng/ml (n = 16) for the E2-treated quail and 3.38 +/- .53 ng/ml (n = 16) for the controls.,Increased clearance rate of plasma thyroxine accompanies estradiol-induced vitellogenesis in male Japanese quail. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095073/),[ng] / [ml],3.38,7028,DB00451,Levothyroxine
,4095073,Clearance rates,Clearance rates of plasma thyroxine were 534 ng thyroxine/100 g/day for the E2-treated quail and 234 ng/100 g/day for the control quail.,Increased clearance rate of plasma thyroxine accompanies estradiol-induced vitellogenesis in male Japanese quail. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095073/),[ine·ng·thyro] / [100·d·g],534,7029,DB00451,Levothyroxine
,4095073,Clearance rates,Clearance rates of plasma thyroxine were 534 ng thyroxine/100 g/day for the E2-treated quail and 234 ng/100 g/day for the control quail.,Increased clearance rate of plasma thyroxine accompanies estradiol-induced vitellogenesis in male Japanese quail. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095073/),[ng] / [100·d·g],234,7030,DB00451,Levothyroxine
,2316313,molar ratio of daily production rates,"Amiodarone, an iodine containing anti-arrhythmic drug, causes a significant decrease in molar ratio of daily production rates of T3 and T4 from 0.75 in controls to 0.36 in amiodarone-treated rabbits.",Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),,0.75,10331,DB00451,Levothyroxine
,2316313,molar ratio of daily production rates,"Amiodarone, an iodine containing anti-arrhythmic drug, causes a significant decrease in molar ratio of daily production rates of T3 and T4 from 0.75 in controls to 0.36 in amiodarone-treated rabbits.",Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),,0.36,10332,DB00451,Levothyroxine
,2316313,metabolic clearance rates,Amiodarone treatment decreased metabolic clearance rates significantly from 0.107 +/- 0.008 in controls to 0.074 +/- 0.009 l/day in amiodarone-treated rabbits (p less than 0.05).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),[l] / [d],0.107,10333,DB00451,Levothyroxine
,2316313,metabolic clearance rates,Amiodarone treatment decreased metabolic clearance rates significantly from 0.107 +/- 0.008 in controls to 0.074 +/- 0.009 l/day in amiodarone-treated rabbits (p less than 0.05).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),[l] / [d],0.074,10334,DB00451,Levothyroxine
,2316313,terminal serum elimination half-life,The terminal serum elimination half-life in the two groups were similar (32.0 +/- 6.7 h in controls vs 49.2 +/- 12.4 h in amiodarone-treated).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),h,32.0,10335,DB00451,Levothyroxine
,2316313,terminal serum elimination half-life,The terminal serum elimination half-life in the two groups were similar (32.0 +/- 6.7 h in controls vs 49.2 +/- 12.4 h in amiodarone-treated).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),h,49.2,10336,DB00451,Levothyroxine
,11372885,half-life,"Fat base concentrations of 2,3,4,7,8-penta-CDF in the Yusho patients, which were responsible for about 70% of the dioxin toxicity, are estimated to be decreased from 60 ppb in 1969 to 800 ppt in 1997 with the median half-life of 2.9 years in the first 15 years after onset and 7.7 years in the next stage of 15 years.",Fate of PCDF/PCB congeners and change of clinical symptoms in patients with Yusho PCB poisoning for 30 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372885/),years,2.9,14410,DB00451,Levothyroxine
,11372885,half-life,"Fat base concentrations of 2,3,4,7,8-penta-CDF in the Yusho patients, which were responsible for about 70% of the dioxin toxicity, are estimated to be decreased from 60 ppb in 1969 to 800 ppt in 1997 with the median half-life of 2.9 years in the first 15 years after onset and 7.7 years in the next stage of 15 years.",Fate of PCDF/PCB congeners and change of clinical symptoms in patients with Yusho PCB poisoning for 30 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372885/),years,7.7,14411,DB00451,Levothyroxine
,23357653,Cmax,"Mixing levothyroxine with different types of dry diet did not have any effect on TT4 pharmacokinetics in the dogs (Cmax 50.6 nmol/L, tmax 4.0 h and AUC 517 nmol h/L).",Effects of type of diet on pharmacokinetics of levothyroxine sodium oral solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357653/),[nM] / [l],50.6,14914,DB00451,Levothyroxine
,23357653,tmax,"Mixing levothyroxine with different types of dry diet did not have any effect on TT4 pharmacokinetics in the dogs (Cmax 50.6 nmol/L, tmax 4.0 h and AUC 517 nmol h/L).",Effects of type of diet on pharmacokinetics of levothyroxine sodium oral solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357653/),h,4.0,14915,DB00451,Levothyroxine
,23357653,AUC,"Mixing levothyroxine with different types of dry diet did not have any effect on TT4 pharmacokinetics in the dogs (Cmax 50.6 nmol/L, tmax 4.0 h and AUC 517 nmol h/L).",Effects of type of diet on pharmacokinetics of levothyroxine sodium oral solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357653/),[h·nM] / [l],517,14916,DB00451,Levothyroxine
,22116076,time to peak blood level,The median time to peak blood level was determined to be at 8 hours post dose.,Innovative studies in women by use of stabilized isotopes in pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116076/),h,8,16803,DB00451,Levothyroxine
,3964797,systemic clearance,"During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).",Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],234,16923,DB00451,Levothyroxine
,3964797,systemic clearance,"During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).",Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],172,16924,DB00451,Levothyroxine
,3964797,renal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],105,16925,DB00451,Levothyroxine
,3964797,renal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],84,16926,DB00451,Levothyroxine
,3964797,nonrenal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],130,16927,DB00451,Levothyroxine
,3964797,nonrenal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],88,16928,DB00451,Levothyroxine
,3964797,half-life of elimination,Digoxin half-life of elimination was prolonged from 34 +/- 13 to 40 +/- 16 hours (p less than 0.05).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),h,34,16929,DB00451,Levothyroxine
,3964797,half-life of elimination,Digoxin half-life of elimination was prolonged from 34 +/- 13 to 40 +/- 16 hours (p less than 0.05).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),h,40,16930,DB00451,Levothyroxine
,19808952,area under the concentration-time curve ratios,Triiodothyronine administration significantly reduced the area under the concentration-time curve ratios for 1'-hydroxymidazolam/midazolam from 0.36 to 0.25 (P < .05) and urinary ratios of 6 beta-hydroxycortisol/free cortisol from 6.92 to 5.88 (P < .05).,Effect of thyroid hormone on the activity of CYP3A enzyme in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19808952/),,0.,21070,DB00451,Levothyroxine
,3708866,plasma clearance,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[ml] / [d·kg],64,23422,DB00451,Levothyroxine
,3708866,plasma clearance,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[ml] / [d·kg],109,23423,DB00451,Levothyroxine
,3708866,production rate,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[nM] / [d·kg],3.8,23424,DB00451,Levothyroxine
,3708866,production rate,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[nM] / [d·kg],3.7,23425,DB00451,Levothyroxine
,7083508,indirect,"The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days).",Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083508/),d,35,24046,DB00451,Levothyroxine
,7083508,therapeutic half-life,"The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days).",Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083508/),d,25 to 55,24047,DB00451,Levothyroxine
,7083508,therapeutic half-life,"The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days).",Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083508/),d,35,24048,DB00451,Levothyroxine
,14697084,maximal serum concentration,"We estimate that the maximal serum concentration after the intake of the latest capsule could be 794.3 nmol/l, i.e. 397 times higher than the mean normal value.",[Triiodothyronine intoxication. A clinical and phamacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697084/),[nM] / [l],794.3,28389,DB00451,Levothyroxine
,14697084,elimination half-life,The elimination half-life was 24 hours 40 minutes.,[Triiodothyronine intoxication. A clinical and phamacokinetic study]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697084/),h,24,28390,DB00451,Levothyroxine
,14697084,elimination half-life,The elimination half-life was 24 hours 40 minutes.,[Triiodothyronine intoxication. A clinical and phamacokinetic study]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697084/),min,40,28391,DB00451,Levothyroxine
,2598470,urinary sodium excretion,Bio-hGH administration resulted in a significant increase in body weight (80.0 +/- 4.5 to 81.1 +/- 4.3 kg; P less than 0.01) which was associated with a marked reduction in urinary sodium excretion (196 +/- 38 to 45 +/- 20 mmol/day; P less than 0.025).,"The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598470/),[mM] / [d],196,29974,DB00451,Levothyroxine
,2598470,urinary sodium excretion,Bio-hGH administration resulted in a significant increase in body weight (80.0 +/- 4.5 to 81.1 +/- 4.3 kg; P less than 0.01) which was associated with a marked reduction in urinary sodium excretion (196 +/- 38 to 45 +/- 20 mmol/day; P less than 0.025).,"The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598470/),[mM] / [d],45,29975,DB00451,Levothyroxine
,1726900,t1/2,The TRH-degradation curves showed similar exponential decay before and after improvement of metabolic control (t1/2: 7.6 +/- 0.4 min and 7.3 +/- 0.3 respectively; 6.5 +/- 0.4 min for the controls).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),min,7.6,31195,DB00451,Levothyroxine
,1726900,t1/2,The TRH-degradation curves showed similar exponential decay before and after improvement of metabolic control (t1/2: 7.6 +/- 0.4 min and 7.3 +/- 0.3 respectively; 6.5 +/- 0.4 min for the controls).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),,7.3,31196,DB00451,Levothyroxine
,1726900,t1/2,The TRH-degradation curves showed similar exponential decay before and after improvement of metabolic control (t1/2: 7.6 +/- 0.4 min and 7.3 +/- 0.3 respectively; 6.5 +/- 0.4 min for the controls).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),min,6.5,31197,DB00451,Levothyroxine
,1726900,MCR,The MCR of exogenously administered TRH in IDDM before (65.5 +/- 8.6 l/m2/day) and after (65.0 +/- 8.9) control was not different compared to the normals (76.5 +/- 9.6).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[l] / [d·m2],65.5,31198,DB00451,Levothyroxine
,1726900,MCR,The MCR of exogenously administered TRH in IDDM before (65.5 +/- 8.6 l/m2/day) and after (65.0 +/- 8.9) control was not different compared to the normals (76.5 +/- 9.6).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),,65.0,31199,DB00451,Levothyroxine
,1726900,MCR,The MCR of exogenously administered TRH in IDDM before (65.5 +/- 8.6 l/m2/day) and after (65.0 +/- 8.9) control was not different compared to the normals (76.5 +/- 9.6).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[l] / [d·m2],76.5,31200,DB00451,Levothyroxine
,1726900,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) in IDDM before (52.193 +/- 6.773 fmoles.ml-1.min) and after improvement of metabolic control (53.186 +/- 7.856) was slightly higher than in the healthy subjects (40.151 +/- 3.741, n.s.).",Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[fmoles·min] / [ml],52.193,31201,DB00451,Levothyroxine
,1726900,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) in IDDM before (52.193 +/- 6.773 fmoles.ml-1.min) and after improvement of metabolic control (53.186 +/- 7.856) was slightly higher than in the healthy subjects (40.151 +/- 3.741, n.s.).",Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[fmoles·min] / [ml],53.186,31202,DB00451,Levothyroxine
,1726900,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) in IDDM before (52.193 +/- 6.773 fmoles.ml-1.min) and after improvement of metabolic control (53.186 +/- 7.856) was slightly higher than in the healthy subjects (40.151 +/- 3.741, n.s.).",Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[fmoles·min] / [ml],40.151,31203,DB00451,Levothyroxine
,33280111,time to maximum plasma concentration,"Median (range) CBD time to maximum plasma concentration, maximum plasma concentration, and area under the concentration versus time curve up to 6 hours after dosing were 3.2 hours (1.9-6.2), 49.6 ng/mL (14.4-302.0), and 226.3 ng ⋅ h/mL (70.5-861.3), respectively.",Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280111/),h,3.2,39085,DB00451,Levothyroxine
,33280111,maximum plasma concentration,"Median (range) CBD time to maximum plasma concentration, maximum plasma concentration, and area under the concentration versus time curve up to 6 hours after dosing were 3.2 hours (1.9-6.2), 49.6 ng/mL (14.4-302.0), and 226.3 ng ⋅ h/mL (70.5-861.3), respectively.",Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280111/),[ng] / [ml],49.6,39086,DB00451,Levothyroxine
,33280111,area under the concentration versus time curve up to 6 hours,"Median (range) CBD time to maximum plasma concentration, maximum plasma concentration, and area under the concentration versus time curve up to 6 hours after dosing were 3.2 hours (1.9-6.2), 49.6 ng/mL (14.4-302.0), and 226.3 ng ⋅ h/mL (70.5-861.3), respectively.",Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280111/),[h·ng] / [ml],226.3,39087,DB00451,Levothyroxine
,29589994,Mage,Ten subjects (Mage ± SD = 33.7 ± 10.2 years; 60% male) completed the study.,Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),,33.7,40286,DB00451,Levothyroxine
,29589994,area under the curve (AUC),The area under the curve (AUC) of TT4 concentrations was significantly lower when levothyroxine was ingested along with 12 oz (355 mL) of 2% cow's milk (M ± SD = 67.3 ± 12.1) compared to that with levothyroxine alone (73.5 ± 17.0; p = 0.02).,Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),,67.3,40287,DB00451,Levothyroxine
,29589994,area under the curve (AUC),The area under the curve (AUC) of TT4 concentrations was significantly lower when levothyroxine was ingested along with 12 oz (355 mL) of 2% cow's milk (M ± SD = 67.3 ± 12.1) compared to that with levothyroxine alone (73.5 ± 17.0; p = 0.02).,Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),,73.5,40288,DB00451,Levothyroxine
,29589994,peak serum TT4 concentrations,"Also, peak serum TT4 concentrations were significantly lower when cow's milk was co-administered with levothyroxine (M ± SD = 14.1 ± 0.8 μg/dL) than with levothyroxine alone (13.0 ± 0.9 μg/dL; p = 0.04).",Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),[μg] / [dl],14.1,40289,DB00451,Levothyroxine
,29589994,peak serum TT4 concentrations,"Also, peak serum TT4 concentrations were significantly lower when cow's milk was co-administered with levothyroxine (M ± SD = 14.1 ± 0.8 μg/dL) than with levothyroxine alone (13.0 ± 0.9 μg/dL; p = 0.04).",Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),[μg] / [dl],13.0,40290,DB00451,Levothyroxine
,11304941,Cmax,"The mean pharmacokinetic parameters for total T4, expressed as geometric means (CV), for the test and reference were, respectively: Cmax (microgram/dl) 9.8 (14.3%) and 10.8 (14.9%); AUC0-24 h (microgram/dl.h) 206.8 (13.9%) and 230.4 (14.9%).",Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304941/),[μg] / [dl],9.8,43689,DB00451,Levothyroxine
,11304941,Cmax,"The mean pharmacokinetic parameters for total T4, expressed as geometric means (CV), for the test and reference were, respectively: Cmax (microgram/dl) 9.8 (14.3%) and 10.8 (14.9%); AUC0-24 h (microgram/dl.h) 206.8 (13.9%) and 230.4 (14.9%).",Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304941/),,10.8,43690,DB00451,Levothyroxine
,11304941,AUC0-24 h,"The mean pharmacokinetic parameters for total T4, expressed as geometric means (CV), for the test and reference were, respectively: Cmax (microgram/dl) 9.8 (14.3%) and 10.8 (14.9%); AUC0-24 h (microgram/dl.h) 206.8 (13.9%) and 230.4 (14.9%).",Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304941/),[μg] / [dl·h],206.8,43691,DB00451,Levothyroxine
,11304941,AUC0-24 h,"The mean pharmacokinetic parameters for total T4, expressed as geometric means (CV), for the test and reference were, respectively: Cmax (microgram/dl) 9.8 (14.3%) and 10.8 (14.9%); AUC0-24 h (microgram/dl.h) 206.8 (13.9%) and 230.4 (14.9%).",Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304941/),,230.4,43692,DB00451,Levothyroxine
,11304941,Tmax,"Median values (90% CI) for Tmax (h) were 3 (2-3) and 2 (2-4) for the test and reference, respectively.",Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304941/),h,3,43693,DB00451,Levothyroxine
,11304941,Tmax,"Median values (90% CI) for Tmax (h) were 3 (2-3) and 2 (2-4) for the test and reference, respectively.",Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304941/),h,2,43694,DB00451,Levothyroxine
,27128831,half-life,"Bazedoxifene demonstrated a half-life of 25 to 30 hours, reached steady state within 7 days, and exhibited linear pharmacokinetics over a dose range of 5-80 mg.","A double-blind, randomized, ascending, multiple-dose study of bazedoxifene in healthy postmenopausal women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128831/),h,25 to 30,44475,DB00451,Levothyroxine
exceeding,17107884,binding stoichiometry,"In the 250 mg bid group, 12 h after the 13th oral dose, the diflunisal serum concentration of 146 +/- 39 microM was sufficient to afford a TTR binding stoichiometry exceeding 0.95 +/- 0.13 ( approximately 1.75 corrected).",Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107884/),,0.95,46333,DB00451,Levothyroxine
,2898717,peak levels,"The plasma concentrations of SMS were dose-responsive and the peak levels were 1.61 +/- 0.09, 4.91 +/- 0.30 and 8.52 +/- 1.18 ng/ml, which were observed at 30, 15 and 45 min after the injection of 25, 50 and 100 micrograms of SMS, respectively.",Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),[ng] / [ml],1.61,52972,DB00451,Levothyroxine
,2898717,peak levels,"The plasma concentrations of SMS were dose-responsive and the peak levels were 1.61 +/- 0.09, 4.91 +/- 0.30 and 8.52 +/- 1.18 ng/ml, which were observed at 30, 15 and 45 min after the injection of 25, 50 and 100 micrograms of SMS, respectively.",Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),[ng] / [ml],4.91,52973,DB00451,Levothyroxine
,2898717,peak levels,"The plasma concentrations of SMS were dose-responsive and the peak levels were 1.61 +/- 0.09, 4.91 +/- 0.30 and 8.52 +/- 1.18 ng/ml, which were observed at 30, 15 and 45 min after the injection of 25, 50 and 100 micrograms of SMS, respectively.",Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),[ng] / [ml],8.52,52974,DB00451,Levothyroxine
,2898717,plasma disappearance half-time,Mean plasma disappearance half-time of SMS was estimated to be 110 +/- 3 min.,Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),min,110,52975,DB00451,Levothyroxine
,16485577,effective half-life,"The effective half-life of 131I was 0.59-0.69 days (group G1.1), 0.87-1.22 days (group G1.2) and 0.38-0.44 days (group G2).",Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485577/),d,0.59-0.69,59184,DB00451,Levothyroxine
,16485577,effective half-life,"The effective half-life of 131I was 0.59-0.69 days (group G1.1), 0.87-1.22 days (group G1.2) and 0.38-0.44 days (group G2).",Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485577/),d,0.87-1.22,59185,DB00451,Levothyroxine
,16485577,effective half-life,"The effective half-life of 131I was 0.59-0.69 days (group G1.1), 0.87-1.22 days (group G1.2) and 0.38-0.44 days (group G2).",Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485577/),d,0.38-0.44,59186,DB00451,Levothyroxine
,3549956,PR,"The PR of angiotensinogen increased from 576 +/- 28 (S.E.M.; n = 9) to 954 +/- 63 (n = 9), 1010 +/- 84 (n = 9) and 2359 +/- 150 (n = 10) micrograms/h per kg following treatment with CA, OB and T4 respectively.",Production and metabolic clearance of angiotensinogen in conscious rats as measured by steady-state isotope dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549956/),[μg] / [h·kg],576,62497,DB00451,Levothyroxine
,3549956,PR,"The PR of angiotensinogen increased from 576 +/- 28 (S.E.M.; n = 9) to 954 +/- 63 (n = 9), 1010 +/- 84 (n = 9) and 2359 +/- 150 (n = 10) micrograms/h per kg following treatment with CA, OB and T4 respectively.",Production and metabolic clearance of angiotensinogen in conscious rats as measured by steady-state isotope dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549956/),[μg] / [h·kg],954,62498,DB00451,Levothyroxine
,3549956,PR,"The PR of angiotensinogen increased from 576 +/- 28 (S.E.M.; n = 9) to 954 +/- 63 (n = 9), 1010 +/- 84 (n = 9) and 2359 +/- 150 (n = 10) micrograms/h per kg following treatment with CA, OB and T4 respectively.",Production and metabolic clearance of angiotensinogen in conscious rats as measured by steady-state isotope dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549956/),[μg] / [h·kg],1010,62499,DB00451,Levothyroxine
,3549956,PR,"The PR of angiotensinogen increased from 576 +/- 28 (S.E.M.; n = 9) to 954 +/- 63 (n = 9), 1010 +/- 84 (n = 9) and 2359 +/- 150 (n = 10) micrograms/h per kg following treatment with CA, OB and T4 respectively.",Production and metabolic clearance of angiotensinogen in conscious rats as measured by steady-state isotope dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549956/),[μg] / [h·kg],2359,62500,DB00451,Levothyroxine
,3549956,PR,"In contrast, the PR of rat albumin did not change significantly from 218 +/- 8 (n = 7) mg/h per kg.",Production and metabolic clearance of angiotensinogen in conscious rats as measured by steady-state isotope dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549956/),[mg] / [h·kg],218,62501,DB00451,Levothyroxine
,3549956,MCR,"All three hormones increased MCR from 13 +/- 1 (n = 17) ml/h per kg to 17 +/- 1 (n = 9), 18 +/- 2 (n = 9) and 27 +/- 2 (n = 9) ml/h per kg for CA, OB and T4 respectively.",Production and metabolic clearance of angiotensinogen in conscious rats as measured by steady-state isotope dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549956/),[ml] / [h·kg],13,62502,DB00451,Levothyroxine
,3549956,MCR,"All three hormones increased MCR from 13 +/- 1 (n = 17) ml/h per kg to 17 +/- 1 (n = 9), 18 +/- 2 (n = 9) and 27 +/- 2 (n = 9) ml/h per kg for CA, OB and T4 respectively.",Production and metabolic clearance of angiotensinogen in conscious rats as measured by steady-state isotope dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549956/),[ml] / [h·kg],17,62503,DB00451,Levothyroxine
,3549956,MCR,"All three hormones increased MCR from 13 +/- 1 (n = 17) ml/h per kg to 17 +/- 1 (n = 9), 18 +/- 2 (n = 9) and 27 +/- 2 (n = 9) ml/h per kg for CA, OB and T4 respectively.",Production and metabolic clearance of angiotensinogen in conscious rats as measured by steady-state isotope dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549956/),[ml] / [h·kg],18,62504,DB00451,Levothyroxine
,3549956,MCR,"All three hormones increased MCR from 13 +/- 1 (n = 17) ml/h per kg to 17 +/- 1 (n = 9), 18 +/- 2 (n = 9) and 27 +/- 2 (n = 9) ml/h per kg for CA, OB and T4 respectively.",Production and metabolic clearance of angiotensinogen in conscious rats as measured by steady-state isotope dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549956/),[ml] / [h·kg],27,62505,DB00451,Levothyroxine
,22932947,TSH,"In the other 7 patients, post-switch TSH was 0.41 ± 0.46 (PH) versus 0.28 ± 0.20 pre-switch (PH) (P = 0.61) and 0.34 ± 0.30 (IH) versus 1.23 ± 1.47 pre-switch (IH) (P < 0.001).",A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22932947/),,0.28,64269,DB00451,Levothyroxine
,22932947,TSH,"In the other 7 patients, post-switch TSH was 0.41 ± 0.46 (PH) versus 0.28 ± 0.20 pre-switch (PH) (P = 0.61) and 0.34 ± 0.30 (IH) versus 1.23 ± 1.47 pre-switch (IH) (P < 0.001).",A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22932947/),,0.34,64270,DB00451,Levothyroxine
,22932947,TSH,"In the other 7 patients, post-switch TSH was 0.41 ± 0.46 (PH) versus 0.28 ± 0.20 pre-switch (PH) (P = 0.61) and 0.34 ± 0.30 (IH) versus 1.23 ± 1.47 pre-switch (IH) (P < 0.001).",A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22932947/),,1.23,64271,DB00451,Levothyroxine
,2924068,steady state distribution volume,The steady state distribution volume of ajmaline decreased from 4.81 l kg-1 in control rats to 3.80 l kg-1 in hyperthyroid rats and the total body blood clearance was slightly higher in hyperthyroid rats than in control rats.,Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924068/),[l] / [kg],4.81,65240,DB00451,Levothyroxine
,2924068,steady state distribution volume,The steady state distribution volume of ajmaline decreased from 4.81 l kg-1 in control rats to 3.80 l kg-1 in hyperthyroid rats and the total body blood clearance was slightly higher in hyperthyroid rats than in control rats.,Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924068/),[l] / [kg],3.80,65241,DB00451,Levothyroxine
,30301431,plateau time,"Furthermore, the plateau time, that is, the time-span during which the serum T3 concentration is at least half of T3 peak, increased from 4.9 to 7.7 hours in LT3- versus PZL-treated rats, respectively.",Metal Coordinated Poly-Zinc-Liothyronine Provides Stable Circulating Triiodothyronine Levels in Hypothyroid Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30301431/),h,4.9,65254,DB00451,Levothyroxine
,30301431,plateau time,"Furthermore, the plateau time, that is, the time-span during which the serum T3 concentration is at least half of T3 peak, increased from 4.9 to 7.7 hours in LT3- versus PZL-treated rats, respectively.",Metal Coordinated Poly-Zinc-Liothyronine Provides Stable Circulating Triiodothyronine Levels in Hypothyroid Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30301431/),h,7.7,65255,DB00451,Levothyroxine
,1900321,t1/2,"PCR, t1/2 and t1/2p were 22.1 +/- 3.4 ml/kg per min, 6.8 +/- 1.1 min and 17.3 +/- 6.7 min (means +/- S.D.) respectively in the euthyroid patients.",Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),[ml] / [kg·min],22.1,66960,DB00451,Levothyroxine
,1900321,t1/2p,"PCR, t1/2 and t1/2p were 22.1 +/- 3.4 ml/kg per min, 6.8 +/- 1.1 min and 17.3 +/- 6.7 min (means +/- S.D.) respectively in the euthyroid patients.",Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),min,17.3,66961,DB00451,Levothyroxine
,1900321,t1/2,The t1/2 was 5.6 min in the hyperthyroid patients compared with 9.4 min in the hypothyroid patients.,Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),min,5.6,66962,DB00451,Levothyroxine
,1900321,t1/2,The t1/2 was 5.6 min in the hyperthyroid patients compared with 9.4 min in the hypothyroid patients.,Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),min,9.4,66963,DB00451,Levothyroxine
,1900321,t1/2t,The calculated t1/2t was 6.5 min in the euthyroid patients.,Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),min,6.5,66964,DB00451,Levothyroxine
,26191653,AUC,"A trend toward reduced TT4 AUC was observed after metformin ingestion (pre-metformin 3893 ± 568 μg/dL-min, post-metformin 3765 ± 588 μg/dL-min, p = 0.09).",Metformin Does Not Suppress Serum Thyrotropin by Increasing Levothyroxine Absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26191653/),[μg] / [dl-min],3893,68301,DB00451,Levothyroxine
,26191653,AUC,"A trend toward reduced TT4 AUC was observed after metformin ingestion (pre-metformin 3893 ± 568 μg/dL-min, post-metformin 3765 ± 588 μg/dL-min, p = 0.09).",Metformin Does Not Suppress Serum Thyrotropin by Increasing Levothyroxine Absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26191653/),[μg] / [dl-min],3765,68302,DB00451,Levothyroxine
,18307500,t(max),L-T4 was absorbed fairly rapidly (t(max) 3 h).,Pharmacokinetics of total thyroxine in dogs after administration of an oral solution of levothyroxine sodium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307500/),h,3,70271,DB00451,Levothyroxine
,18307500,bioavailability,A mean bioavailability of 22% was calculated following a single oral administration of 40 microg L-T4/kg body weight.,Pharmacokinetics of total thyroxine in dogs after administration of an oral solution of levothyroxine sodium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307500/),%,22,70272,DB00451,Levothyroxine
,18307500,serum half-life,"After intravenous administration of L-T4, a serum half-life of 11.6 h was calculated.",Pharmacokinetics of total thyroxine in dogs after administration of an oral solution of levothyroxine sodium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307500/),h,11.6,70273,DB00451,Levothyroxine
,18307500,relative bioavailability,The relative bioavailability of L-T4 following administration of a tablet formulation was about 50% of that of the L-T4 solution.,Pharmacokinetics of total thyroxine in dogs after administration of an oral solution of levothyroxine sodium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307500/),%,50,70274,DB00451,Levothyroxine
,1487553,area under the curve (AUC) (0 to 48 hours),"Statistically significant differences for area under the curve (AUC) (0 to 48 hours) (formulation A, 159.9 +/- 9.4 micrograms-hour/dL; formulation B, 193.4 +/- 10.1 micrograms-hour/dL) and maximum peak plasma concentration (Cmax) (formulation A, 5.91 +/- .34; formulation B, 7.12 +/- .32) also were demonstrated.",A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487553/),[μgrams-hour] / [dl],159.9,70580,DB00451,Levothyroxine
,1487553,area under the curve (AUC) (0 to 48 hours),"Statistically significant differences for area under the curve (AUC) (0 to 48 hours) (formulation A, 159.9 +/- 9.4 micrograms-hour/dL; formulation B, 193.4 +/- 10.1 micrograms-hour/dL) and maximum peak plasma concentration (Cmax) (formulation A, 5.91 +/- .34; formulation B, 7.12 +/- .32) also were demonstrated.",A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487553/),[μgrams-hour] / [dl],193.4,70581,DB00451,Levothyroxine
,1487553,maximum peak plasma concentration (Cmax),"Statistically significant differences for area under the curve (AUC) (0 to 48 hours) (formulation A, 159.9 +/- 9.4 micrograms-hour/dL; formulation B, 193.4 +/- 10.1 micrograms-hour/dL) and maximum peak plasma concentration (Cmax) (formulation A, 5.91 +/- .34; formulation B, 7.12 +/- .32) also were demonstrated.",A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487553/),,5.91,70582,DB00451,Levothyroxine
,1487553,maximum peak plasma concentration (Cmax),"Statistically significant differences for area under the curve (AUC) (0 to 48 hours) (formulation A, 159.9 +/- 9.4 micrograms-hour/dL; formulation B, 193.4 +/- 10.1 micrograms-hour/dL) and maximum peak plasma concentration (Cmax) (formulation A, 5.91 +/- .34; formulation B, 7.12 +/- .32) also were demonstrated.",A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487553/),,7.12,70583,DB00451,Levothyroxine
<,11850686,half-lives,"However, for patients with extremely short levothyroxine half-lives (<2--3 days), larger errors in AUC values are possible.",Simulations of Levothyroxine Bioavailability Using a Single-Dose Study Protocol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850686/),d,2--3,77816,DB00451,Levothyroxine
,3238320,MCR,"Median DIT MCR was in eight healthy subjects estimated to 162 l/day x 70 kg (range 135-242), whereas PR was 52 nmol/day x 70 kg (range 25-126).",Metabolic clearance and production of diiodotyrosine in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3238320/),[l] / [70·d·kg],162,80220,DB00451,Levothyroxine
,3238320,PR,"Median DIT MCR was in eight healthy subjects estimated to 162 l/day x 70 kg (range 135-242), whereas PR was 52 nmol/day x 70 kg (range 25-126).",Metabolic clearance and production of diiodotyrosine in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3238320/),[nM] / [70·d·kg],52,80221,DB00451,Levothyroxine
,3238320,serum,The median serum DIT concentration was 0.27 nmol/l (range 0.16-0.62).,Metabolic clearance and production of diiodotyrosine in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3238320/),[nM] / [l],0.27,80222,DB00451,Levothyroxine
,3238320,concentration,The median serum DIT concentration was 0.27 nmol/l (range 0.16-0.62).,Metabolic clearance and production of diiodotyrosine in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3238320/),[nM] / [l],0.27,80223,DB00451,Levothyroxine
,19108789,C(max),"Without adjustment for baseline levels of endogenous levothyroxine, geometric mean C(max) for the test and reference formulations were 8.92 and 9.39 microg/dL, respectively; AUC(0-last) values were 368.40 and 383.37 microg/mL . h(-1).","Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108789/),[μg] / [dl],8.92,83684,DB00451,Levothyroxine
,19108789,C(max),"Without adjustment for baseline levels of endogenous levothyroxine, geometric mean C(max) for the test and reference formulations were 8.92 and 9.39 microg/dL, respectively; AUC(0-last) values were 368.40 and 383.37 microg/mL . h(-1).","Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108789/),[μg] / [dl],9.39,83685,DB00451,Levothyroxine
,19108789,AUC(0-last),"Without adjustment for baseline levels of endogenous levothyroxine, geometric mean C(max) for the test and reference formulations were 8.92 and 9.39 microg/dL, respectively; AUC(0-last) values were 368.40 and 383.37 microg/mL . h(-1).","Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108789/),[ml·μg] / [h],368.40,83686,DB00451,Levothyroxine
,19108789,AUC(0-last),"Without adjustment for baseline levels of endogenous levothyroxine, geometric mean C(max) for the test and reference formulations were 8.92 and 9.39 microg/dL, respectively; AUC(0-last) values were 368.40 and 383.37 microg/mL . h(-1).","Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108789/),[ml·μg] / [h],383.37,83687,DB00451,Levothyroxine
,19108789,C(max),"With adjustment for baseline levels of endogenous levothyroxine, the geometric mean C(max) for the test and reference formulations were 3.16 and 3.39 microg/dL, respectively; AUC(0-last) values were 88.33 and 95.60 microg/mL . h(-1).","Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108789/),[μg] / [dl],3.16,83688,DB00451,Levothyroxine
,19108789,C(max),"With adjustment for baseline levels of endogenous levothyroxine, the geometric mean C(max) for the test and reference formulations were 3.16 and 3.39 microg/dL, respectively; AUC(0-last) values were 88.33 and 95.60 microg/mL . h(-1).","Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108789/),[μg] / [dl],3.39,83689,DB00451,Levothyroxine
,19108789,AUC(0-last),"With adjustment for baseline levels of endogenous levothyroxine, the geometric mean C(max) for the test and reference formulations were 3.16 and 3.39 microg/dL, respectively; AUC(0-last) values were 88.33 and 95.60 microg/mL . h(-1).","Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108789/),[ml·μg] / [h],88.33,83690,DB00451,Levothyroxine
,19108789,AUC(0-last),"With adjustment for baseline levels of endogenous levothyroxine, the geometric mean C(max) for the test and reference formulations were 3.16 and 3.39 microg/dL, respectively; AUC(0-last) values were 88.33 and 95.60 microg/mL . h(-1).","Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108789/),[ml·μg] / [h],95.60,83691,DB00451,Levothyroxine
,20962709,area under the curve,"The area under the curve was 23.0 ng*h/mL in pregnancy and 14.8 ng*h/mL in nonpregnant women (P < 0.03) with median serum half-lives of 32.1 hours and 24.1 hours, respectively (P < 0.04).",Longitudinal comparison of thyroxine pharmacokinetics between pregnant and nonpregnant women: a stable isotope study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962709/),[h·ng] / [ml],23.0,84729,DB00451,Levothyroxine
,20962709,area under the curve,"The area under the curve was 23.0 ng*h/mL in pregnancy and 14.8 ng*h/mL in nonpregnant women (P < 0.03) with median serum half-lives of 32.1 hours and 24.1 hours, respectively (P < 0.04).",Longitudinal comparison of thyroxine pharmacokinetics between pregnant and nonpregnant women: a stable isotope study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962709/),[h·ng] / [ml],14.8,84730,DB00451,Levothyroxine
,20962709,serum half-lives,"The area under the curve was 23.0 ng*h/mL in pregnancy and 14.8 ng*h/mL in nonpregnant women (P < 0.03) with median serum half-lives of 32.1 hours and 24.1 hours, respectively (P < 0.04).",Longitudinal comparison of thyroxine pharmacokinetics between pregnant and nonpregnant women: a stable isotope study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962709/),h,32.1,84731,DB00451,Levothyroxine
,20962709,serum half-lives,"The area under the curve was 23.0 ng*h/mL in pregnancy and 14.8 ng*h/mL in nonpregnant women (P < 0.03) with median serum half-lives of 32.1 hours and 24.1 hours, respectively (P < 0.04).",Longitudinal comparison of thyroxine pharmacokinetics between pregnant and nonpregnant women: a stable isotope study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962709/),h,24.1,84732,DB00451,Levothyroxine
,9241288,peak plasma concentration,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[ng] / [ml],50,90826,DB00451,Levothyroxine
,9241288,peak plasma concentration,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[ng] / [ml],73,90827,DB00451,Levothyroxine
,9241288,elimination half life,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),min,4.3,90828,DB00451,Levothyroxine
,9241288,elimination half life,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),min,6.3,90829,DB00451,Levothyroxine
,9241288,area under the curve,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[ng] / [min·ml],156.4,90830,DB00451,Levothyroxine
,9241288,area under the curve,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[ng] / [min·ml],340.1,90831,DB00451,Levothyroxine
,9241288,plasma clearance,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[ml] / [kg·min],45.4,90832,DB00451,Levothyroxine
,9241288,plasma clearance,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[ml] / [kg·min],23.6,90833,DB00451,Levothyroxine
,9241288,volume of distribution,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),%,27.8,90834,DB00451,Levothyroxine
,9241288,volume of distribution,"When given as bolus, mean (+/- standard error of the mean) peak plasma concentration (50 +/- 5.2 and 73 +/- 5.1 ng/mL, P < .01), elimination half life (4.3 +/- 0.3 and 6.3 +/- 0.4 minutes, P < .001), and area under the curve (156.4 +/- 14.8 and 340.1 +/- 32.8 ng/mL/minute, P < .001) in pregnant subjects were reduced compared with controls, whereas plasma clearance (45.4 +/- 6.5 and 23.6 +/- 2.1 mL/kg/minute, P < .01) and volume of distribution (27.8 +/- 1.8 and 19.0 +/- 1.3% body weight, P < .01) were increased.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),%,19.0,90835,DB00451,Levothyroxine
,9241288,steady-state concentration,"When given by infusion, steady-state concentration (6.6 +/- 0.5 and 9.8 +/- 0.9 ng/mL, P < .01) and elimination half-life (4.6 +/- 0.5 and 6.3 +/- 0.3 minutes, P < .05) were lower in pregnant subjects than in controls.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[ng] / [ml],6.6,90836,DB00451,Levothyroxine
,9241288,steady-state concentration,"When given by infusion, steady-state concentration (6.6 +/- 0.5 and 9.8 +/- 0.9 ng/mL, P < .01) and elimination half-life (4.6 +/- 0.5 and 6.3 +/- 0.3 minutes, P < .05) were lower in pregnant subjects than in controls.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[ng] / [ml],9.8,90837,DB00451,Levothyroxine
,9241288,elimination half-life,"When given by infusion, steady-state concentration (6.6 +/- 0.5 and 9.8 +/- 0.9 ng/mL, P < .01) and elimination half-life (4.6 +/- 0.5 and 6.3 +/- 0.3 minutes, P < .05) were lower in pregnant subjects than in controls.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),min,4.6,90838,DB00451,Levothyroxine
,9241288,elimination half-life,"When given by infusion, steady-state concentration (6.6 +/- 0.5 and 9.8 +/- 0.9 ng/mL, P < .01) and elimination half-life (4.6 +/- 0.5 and 6.3 +/- 0.3 minutes, P < .05) were lower in pregnant subjects than in controls.",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),min,6.3,90839,DB00451,Levothyroxine
,9241288,T,"Although basal TSH and thyroid hormone concentrations were similar in patients and controls, the TSH response to TRH was blunted in pregnant subjects compared with controls (9.3 +/- 0.6 and 16.4 +/- 1.4 microIU/mL, P < .001).",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[μiu] / [ml],9.3,90840,DB00451,Levothyroxine
,9241288,response,"Although basal TSH and thyroid hormone concentrations were similar in patients and controls, the TSH response to TRH was blunted in pregnant subjects compared with controls (9.3 +/- 0.6 and 16.4 +/- 1.4 microIU/mL, P < .001).",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[μiu] / [ml],9.3,90841,DB00451,Levothyroxine
,9241288,response,"Although basal TSH and thyroid hormone concentrations were similar in patients and controls, the TSH response to TRH was blunted in pregnant subjects compared with controls (9.3 +/- 0.6 and 16.4 +/- 1.4 microIU/mL, P < .001).",Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[μiu] / [ml],16.4,90842,DB00451,Levothyroxine
,9241288,basal,The basal (3187 +/- 488 and 147 +/- 16 mIU/L) and maximal prolactin response (6193 +/- 426 and 1316 +/- 106 mIU/L) were increased in pregnant subjects compared with controls (P < .001).,Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[miu] / [l],3187,90843,DB00451,Levothyroxine
,9241288,basal,The basal (3187 +/- 488 and 147 +/- 16 mIU/L) and maximal prolactin response (6193 +/- 426 and 1316 +/- 106 mIU/L) were increased in pregnant subjects compared with controls (P < .001).,Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[miu] / [l],147,90844,DB00451,Levothyroxine
,9241288,maximal prolactin response,The basal (3187 +/- 488 and 147 +/- 16 mIU/L) and maximal prolactin response (6193 +/- 426 and 1316 +/- 106 mIU/L) were increased in pregnant subjects compared with controls (P < .001).,Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[miu] / [l],6193,90845,DB00451,Levothyroxine
,9241288,maximal prolactin response,The basal (3187 +/- 488 and 147 +/- 16 mIU/L) and maximal prolactin response (6193 +/- 426 and 1316 +/- 106 mIU/L) were increased in pregnant subjects compared with controls (P < .001).,Pharmacokinetics and pharmacodynamics of TRH during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241288/),[miu] / [l],1316,90846,DB00451,Levothyroxine
,31321670,bioavailability,Differences in bioavailability of 12.5% or more may be considered therapeutically equivalent and therefore such products interchangeable.,Thyroxine and treatment of hypothyroidism: seven decades of experience. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31321670/),%,12.5,91657,DB00451,Levothyroxine
,3435693,clearance,"2. Saliva theophylline clearance (mean +/- s.d. 5.8 +/- 2.1l h-1) was closely related to total plasma theophylline clearance (mean 3.6 +/- 1.2l h-1) (r = 0.958, n = 19, P less than 0.001).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],5.8,97098,DB00451,Levothyroxine
,3435693,total plasma,"2. Saliva theophylline clearance (mean +/- s.d. 5.8 +/- 2.1l h-1) was closely related to total plasma theophylline clearance (mean 3.6 +/- 1.2l h-1) (r = 0.958, n = 19, P less than 0.001).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],3.6,97099,DB00451,Levothyroxine
,3435693,clearance,"2. Saliva theophylline clearance (mean +/- s.d. 5.8 +/- 2.1l h-1) was closely related to total plasma theophylline clearance (mean 3.6 +/- 1.2l h-1) (r = 0.958, n = 19, P less than 0.001).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],3.6,97100,DB00451,Levothyroxine
,3435693,clearance,"3. Saliva theophylline clearance was closely related (r = 0.967, n = 19, P less than 0.001) and numerically very similar to the free plasma theophylline clearance (mean 5.8 +/- 1.9l h-1) (mean difference = 0.06 +/- 0.12 s.e. mean).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],5.8,97101,DB00451,Levothyroxine
,31364488,time to maximum serum concentration,"PK analysis indicates a time to maximum serum concentration of 1.8 ± 0.32 hours and two distinct phases of linear elimination, with a fast distribution phase and slow elimination phases with half-lives of 2.3 ± 0.11 hours and 22.9 ± 7.7 hours, supporting a two-compartment model.",Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364488/),h,1.8,98591,DB00451,Levothyroxine
,31364488,half-lives,"PK analysis indicates a time to maximum serum concentration of 1.8 ± 0.32 hours and two distinct phases of linear elimination, with a fast distribution phase and slow elimination phases with half-lives of 2.3 ± 0.11 hours and 22.9 ± 7.7 hours, supporting a two-compartment model.",Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364488/),h,2.3,98592,DB00451,Levothyroxine
,31364488,half-lives,"PK analysis indicates a time to maximum serum concentration of 1.8 ± 0.32 hours and two distinct phases of linear elimination, with a fast distribution phase and slow elimination phases with half-lives of 2.3 ± 0.11 hours and 22.9 ± 7.7 hours, supporting a two-compartment model.",Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364488/),h,22.9,98593,DB00451,Levothyroxine
,4110897,fractional turnover rate (kT(3)),"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),,0.68,101893,DB00451,Levothyroxine
,4110897,half-life,"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),d,1.0,101894,DB00451,Levothyroxine
,4110897,half-life,"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),d,0.63,101895,DB00451,Levothyroxine
,4110897,half-life,"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),,0.50,101896,DB00451,Levothyroxine
,4110897,half-life,"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),d,1.38,101897,DB00451,Levothyroxine
,4110897,T(3) distribution space,The mean T(3) distribution space in normal subjects was 38.4 liters.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),l,38.4,101898,DB00451,Levothyroxine
,4110897,serum T(3) concentration,The normal serum T(3) concentration was estimated by radioimmunoassay to be 0.106 mug/100 ml.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [100·ml],0.106,101899,DB00451,Levothyroxine
,4110897,T(3) clearance,"Combined with the mean T(3) clearance value of 26.1 liters/day, the calculated T(3) production rate was 27.6 mug/day.",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[l] / [d],26.1,101900,DB00451,Levothyroxine
,4110897,T(3) production rate,"Combined with the mean T(3) clearance value of 26.1 liters/day, the calculated T(3) production rate was 27.6 mug/day.",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [d],27.6,101901,DB00451,Levothyroxine
,4110897,T(3),The mean T(3) production rate increased to 201 mug/day in thyrotoxic Graves' disease patients and was reduced to 7.6 mug/day in primary hypothyroid subjects.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [d],201,101902,DB00451,Levothyroxine
,4110897,production rate,The mean T(3) production rate increased to 201 mug/day in thyrotoxic Graves' disease patients and was reduced to 7.6 mug/day in primary hypothyroid subjects.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [d],201,101903,DB00451,Levothyroxine
,4110897,production rate,The mean T(3) production rate increased to 201 mug/day in thyrotoxic Graves' disease patients and was reduced to 7.6 mug/day in primary hypothyroid subjects.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [d],7.6,101904,DB00451,Levothyroxine
,4110897,ratio of T(3) to,The ratio of T(3) to T(4) production rate in normal subjects was 0.31 and was unchanged in patients with altered TBG values.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),,0,101905,DB00451,Levothyroxine
,9679085,plasma clearance rates,"However, plasma clearance rates (PCR, 5.37 mL/h . 100 g body wt) and plasma appearance rates (PAR3 = PCR x [T3] plasma = 36.3 ng/h . 100 g body wt) were quite different than these indices in rat and human and 5 to 50 times larger than values reported for rainbow trout.","3,5,3'-Triiodothyronine (T3) clearance and T3-glucuronide (T3G) appearance kinetics in plasma of freshwater-reared male tilapia, Oreochromis mossambicus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679085/),[ml] / [100·h],5.37,102390,DB00451,Levothyroxine
,24694613,FT4 level,"The FT4 level during the administration of suppositories was significantly lower than that during the administration of tablets (0.657±0.183 ng/dL vs. 1.25±0.51 ng/dL, p=0.034).",Clinical efficacy and pharmacokinetics of levothyroxine suppository in patients with hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694613/),[ng] / [dl],0.657,102724,DB00451,Levothyroxine
,24694613,FT4 level,"The FT4 level during the administration of suppositories was significantly lower than that during the administration of tablets (0.657±0.183 ng/dL vs. 1.25±0.51 ng/dL, p=0.034).",Clinical efficacy and pharmacokinetics of levothyroxine suppository in patients with hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694613/),[ng] / [dl],1.25,102725,DB00451,Levothyroxine
,2271373,total,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],0.78,104635,DB00451,Levothyroxine
,2271373,unbound clearance,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],1.22,104636,DB00451,Levothyroxine
,2271373,unbound clearance,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],9.3,104637,DB00451,Levothyroxine
,2271373,unbound clearance,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],15.9,104638,DB00451,Levothyroxine
,2271373,elimination half-life,3. The elimination half-life of oxazepam was prolonged by hypothyroidism to a median (range) value of 9.3 h (5.4-21.9) compared with 7.5 h (4.8-10.5) in the euthyroid state (P less than 0.05).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),h,9.3,104639,DB00451,Levothyroxine
,2271373,elimination half-life,3. The elimination half-life of oxazepam was prolonged by hypothyroidism to a median (range) value of 9.3 h (5.4-21.9) compared with 7.5 h (4.8-10.5) in the euthyroid state (P less than 0.05).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),h,7.5,104640,DB00451,Levothyroxine
,2271373,free percentage,4. Hypothyroidism did not affect the protein binding of oxazepam; median values of the free percentage being 8.2% as compared with 7.7% when euthyroid.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),%,8.2,104641,DB00451,Levothyroxine
,2271373,free percentage,4. Hypothyroidism did not affect the protein binding of oxazepam; median values of the free percentage being 8.2% as compared with 7.7% when euthyroid.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),%,7.7,104642,DB00451,Levothyroxine
,2271373,clearance,5. The median (range) clearance of paracetamol under hypothyroid conditions was 3.12 ml min-1 kg-1 (1.64-4.40) and 4.70 ml min-1 kg-1 (3.18-5.70) following replacement therapy (P less than 0.01).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],3.12,104643,DB00451,Levothyroxine
,2271373,clearance,5. The median (range) clearance of paracetamol under hypothyroid conditions was 3.12 ml min-1 kg-1 (1.64-4.40) and 4.70 ml min-1 kg-1 (3.18-5.70) following replacement therapy (P less than 0.01).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],4.70,104644,DB00451,Levothyroxine
,2271373,partial clearance,This increase was associated with a comparable increase in the partial clearance to the glucuronide metabolite: 1.86 ml min-1 kg-1 to 2.70 ml min-1 kg-1.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],1.86,104645,DB00451,Levothyroxine
,2271373,partial clearance,This increase was associated with a comparable increase in the partial clearance to the glucuronide metabolite: 1.86 ml min-1 kg-1 to 2.70 ml min-1 kg-1.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],2.70,104646,DB00451,Levothyroxine
,28774813,Cmax,"Extension of the virtual bioequivalence study to Japanese elderly, who show high incidence of achlorhydria, indicated bio-inequivalence which Cmax and AUC ratios between nifedipine control-released reference and test formulations were 3.08 (90%CI, 2.81-3.38) and 1.57 (90%CI, 1.43-1.74), respectively.",Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28774813/),,3.08,106885,DB00451,Levothyroxine
,28774813,AUC ratios,"Extension of the virtual bioequivalence study to Japanese elderly, who show high incidence of achlorhydria, indicated bio-inequivalence which Cmax and AUC ratios between nifedipine control-released reference and test formulations were 3.08 (90%CI, 2.81-3.38) and 1.57 (90%CI, 1.43-1.74), respectively.",Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28774813/),,1.57,106886,DB00451,Levothyroxine
,12193309,time to peak levels (T(max)),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),min,85.71,107871,DB00451,Levothyroxine
,12193309,T(max),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),min,172.5,107872,DB00451,Levothyroxine
,12193309,T(max),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),[μg] / [ml],2.01,107873,DB00451,Levothyroxine
,12193309,C(max),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),[μg] / [ml],3.89,107874,DB00451,Levothyroxine
,12193309,C(max),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),[μg] / [ml],2.01,107875,DB00451,Levothyroxine
,12193309,area under the curve,"However, the area under the curve (635.16 +/- 105.71 vs.",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),,635.16,107876,DB00451,Levothyroxine
,23110329,AUC,"Following surgery, in the SG group, the mean AUC was higher than it was before surgery (18.97±6.01 vs. 25.048±6.47 [μg/dL]·h; p<0.01), whereas the values of Cmax and Tmax were similar to those before surgery.",Improved levothyroxine pharmacokinetics after bariatric surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110329/),[μg] / [dl]·h],18.97,115187,DB00451,Levothyroxine
,23110329,AUC,"Following surgery, in the SG group, the mean AUC was higher than it was before surgery (18.97±6.01 vs. 25.048±6.47 [μg/dL]·h; p<0.01), whereas the values of Cmax and Tmax were similar to those before surgery.",Improved levothyroxine pharmacokinetics after bariatric surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110329/),[μg] / [dl]·h],25.048,115188,DB00451,Levothyroxine
,23110329,AUC,"In the BPD-LL group, mean AUC and Cmax were higher after surgery than before (14.18±5.64 vs. 25.51±9.1 [μg/dL]·h, p<0.001; 5.62±1.34 vs.",Improved levothyroxine pharmacokinetics after bariatric surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110329/),[μg] / [dl]·h],14.18,115189,DB00451,Levothyroxine
,23110329,Cmax,"In the BPD-LL group, mean AUC and Cmax were higher after surgery than before (14.18±5.64 vs. 25.51±9.1 [μg/dL]·h, p<0.001; 5.62±1.34 vs.",Improved levothyroxine pharmacokinetics after bariatric surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110329/),[μg] / [dl]·h],25.51,115190,DB00451,Levothyroxine
,23110329,Cmax,"In the BPD-LL group, mean AUC and Cmax were higher after surgery than before (14.18±5.64 vs. 25.51±9.1 [μg/dL]·h, p<0.001; 5.62±1.34 vs.",Improved levothyroxine pharmacokinetics after bariatric surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110329/),,5.62,115191,DB00451,Levothyroxine
,6688797,absolute bioavailabilities,"The absolute bioavailabilities of the two tablet preparations were 66% and 72%, respectively.","Pilot study on the absolute and relative bioavailability of Synthroid and Levothroid, two brands of sodium levothyroxine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688797/),%,66,117521,DB00451,Levothyroxine
,6688797,absolute bioavailabilities,"The absolute bioavailabilities of the two tablet preparations were 66% and 72%, respectively.","Pilot study on the absolute and relative bioavailability of Synthroid and Levothroid, two brands of sodium levothyroxine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688797/),%,72,117522,DB00451,Levothyroxine
,2294128,peak amplitude,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],527,120787,DB00451,Levothyroxine
,2294128,peak amplitude,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],331,120788,DB00451,Levothyroxine
,2294128,interpulse valley concentrations,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],384,120789,DB00451,Levothyroxine
,2294128,interpulse valley concentrations,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],204,120790,DB00451,Levothyroxine
,2294128,prepeak nadir concentrations,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],298,120791,DB00451,Levothyroxine
,2294128,prepeak nadir concentrations,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],166,120792,DB00451,Levothyroxine
,2294128,half-life of cort,Analysis of data by a multiple parameter deconvolution method demonstrated a normal 24-h endogenous cortisol production rate in the presence of significantly prolonged subject-specific half-life of cortisol disappearance (155 vs. 73 min; P less than 0.05).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),min,155,120793,DB00451,Levothyroxine
,2294128,half-life of cort,Analysis of data by a multiple parameter deconvolution method demonstrated a normal 24-h endogenous cortisol production rate in the presence of significantly prolonged subject-specific half-life of cortisol disappearance (155 vs. 73 min; P less than 0.05).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),min,73,120794,DB00451,Levothyroxine
,2294128,peak amplitudes,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],527,120795,DB00451,Levothyroxine
,2294128,peak amplitudes,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],375,120796,DB00451,Levothyroxine
,2294128,prepeak nadir concentrations,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],298,120797,DB00451,Levothyroxine
,2294128,prepeak nadir concentrations,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],221,120798,DB00451,Levothyroxine
,2294128,half-life of cortisol disappearance,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),min,155,120799,DB00451,Levothyroxine
,2294128,half-life of cortisol disappearance,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),min,112,120800,DB00451,Levothyroxine
,2588936,cross-reactivity,"An anti-3,5,3'-triiodothyroacetic acid antibody was obtained in rabbits, using 3,5,3'-triiodothyroacetic acid coupled to hemocyanin and diazotized benzidine as antigen (cross-reactivity with T4, T3, tetraiodothyroacetic acid was 0.2, 1.1, and 5%, respectively).","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),%,0.2,121017,DB00451,Levothyroxine
,2588936,cross-reactivity,"An anti-3,5,3'-triiodothyroacetic acid antibody was obtained in rabbits, using 3,5,3'-triiodothyroacetic acid coupled to hemocyanin and diazotized benzidine as antigen (cross-reactivity with T4, T3, tetraiodothyroacetic acid was 0.2, 1.1, and 5%, respectively).","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),%,1.1,121018,DB00451,Levothyroxine
,2588936,cross-reactivity,"An anti-3,5,3'-triiodothyroacetic acid antibody was obtained in rabbits, using 3,5,3'-triiodothyroacetic acid coupled to hemocyanin and diazotized benzidine as antigen (cross-reactivity with T4, T3, tetraiodothyroacetic acid was 0.2, 1.1, and 5%, respectively).","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),%,5,121019,DB00451,Levothyroxine
,2588936,half-life,"The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min +/- 29 min, the volume of distribution was 114 +/- 9 1/70 kg, and the plasma clearance rate was 298 +/- 141.(70 kg)-1.day-1.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),h,6,121020,DB00451,Levothyroxine
,2588936,half-life,"The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min +/- 29 min, the volume of distribution was 114 +/- 9 1/70 kg, and the plasma clearance rate was 298 +/- 141.(70 kg)-1.day-1.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),min,22,121021,DB00451,Levothyroxine
,2588936,volume of distribution,"The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min +/- 29 min, the volume of distribution was 114 +/- 9 1/70 kg, and the plasma clearance rate was 298 +/- 141.(70 kg)-1.day-1.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),[1] / [70·kg],114,121022,DB00451,Levothyroxine
,2588936,plasma clearance rate,"The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min +/- 29 min, the volume of distribution was 114 +/- 9 1/70 kg, and the plasma clearance rate was 298 +/- 141.(70 kg)-1.day-1.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),1/[d·kg],298,121023,DB00451,Levothyroxine
,2588936,potency ratio,"In conclusion, TSH inhibition by 3,5,3'-triiodothyroacetic acid is similar to T3, with a potency ratio of 1 to 18.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),,1 to 18,121024,DB00451,Levothyroxine
,427223,half-life,"The half-life of physiologically radioiodinated asialothyroglobulins was about 6 min, while that of chemically radioiodinated asialothyroglobulin was about 12 min.",Clearance of circulating desialylated thyroglobulins in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427223/),min,6,124698,DB00451,Levothyroxine
,427223,half-life,"The half-life of physiologically radioiodinated asialothyroglobulins was about 6 min, while that of chemically radioiodinated asialothyroglobulin was about 12 min.",Clearance of circulating desialylated thyroglobulins in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427223/),min,12,124699,DB00451,Levothyroxine
,4032047,RAIU,"Conditions modeled included radioactive iodine uptake (RAIU) values of 0%, 1%, 5%, 15% and 25%, and RAIU of 15% combined with various degrees of pharmacologic block of thyroidal RAIU.",Radiation dosimetry of radioiodinated thyroid hormones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032047/),%,15,127485,DB00451,Levothyroxine
,29209276,FT4,"In the first six patients, postswitch FT4 averaged 13.0 ± 1.6 pg/ml compared to 10.4 ± 1.8 preswitch FT4 (P = 0.00026), with 11/13 (85%) measurements above MNRV compared to 0/20.",l-Thyroxine in an Oral Liquid or Softgel Formulation Ensures More Normal Serum Levels of Free T4 in Patients with Central Hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29209276/),[pg] / [ml],13.0,128270,DB00451,Levothyroxine
,29209276,FT4,"In the first six patients, postswitch FT4 averaged 13.0 ± 1.6 pg/ml compared to 10.4 ± 1.8 preswitch FT4 (P = 0.00026), with 11/13 (85%) measurements above MNRV compared to 0/20.",l-Thyroxine in an Oral Liquid or Softgel Formulation Ensures More Normal Serum Levels of Free T4 in Patients with Central Hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29209276/),,10.4,128271,DB00451,Levothyroxine
,29209276,FT4,"In the liquid or softgel l-T4 group, postswitch FT4 averaged 13.1 ± 1.6 vs.",l-Thyroxine in an Oral Liquid or Softgel Formulation Ensures More Normal Serum Levels of Free T4 in Patients with Central Hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29209276/),,13.1,128272,DB00451,Levothyroxine
,24773132,tT4 concentration,"Before dosing for pharmacokinetic evaluation, mean tT4 concentration was 23 ± 9 nmol/L. l-T4 was absorbed rapidly (tmax , 5 hours), reaching a mean maximal tT4 concentration of 56 ± 11 nmol/L.",Pharmacokinetics of total thyroxine after repeated oral administration of levothyroxine solution and its clinical efficacy in hypothyroid dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24773132/),[nM] / [l·l],23,135328,DB00451,Levothyroxine
,24773132,tmax,"Before dosing for pharmacokinetic evaluation, mean tT4 concentration was 23 ± 9 nmol/L. l-T4 was absorbed rapidly (tmax , 5 hours), reaching a mean maximal tT4 concentration of 56 ± 11 nmol/L.",Pharmacokinetics of total thyroxine after repeated oral administration of levothyroxine solution and its clinical efficacy in hypothyroid dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24773132/),h,5,135329,DB00451,Levothyroxine
,24773132,maximal tT4 concentration,"Before dosing for pharmacokinetic evaluation, mean tT4 concentration was 23 ± 9 nmol/L. l-T4 was absorbed rapidly (tmax , 5 hours), reaching a mean maximal tT4 concentration of 56 ± 11 nmol/L.",Pharmacokinetics of total thyroxine after repeated oral administration of levothyroxine solution and its clinical efficacy in hypothyroid dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24773132/),[nM] / [l],56,135330,DB00451,Levothyroxine
,24773132,apparent terminal half-life,The apparent terminal half-life was 11.8 hours.,Pharmacokinetics of total thyroxine after repeated oral administration of levothyroxine solution and its clinical efficacy in hypothyroid dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24773132/),h,11.8,135331,DB00451,Levothyroxine
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],2.09,136631,DB00451,Levothyroxine
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],1.78,136632,DB00451,Levothyroxine
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],68.1,136633,DB00451,Levothyroxine
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],64.3,136634,DB00451,Levothyroxine
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.00,136635,DB00451,Levothyroxine
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.02,136636,DB00451,Levothyroxine
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,24.0,136637,DB00451,Levothyroxine
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,25.7,136638,DB00451,Levothyroxine
,23438458,maximum plasma concentration,"Following oral administration of the reference tablet at the dose of 100 μg/kg, a maximum plasma concentration of approximately 96.2 nmol/L (baseline endogenous corrected) was reached within 3.77 h.",Bioavailability of two L-thyroxine formulations after oral administration to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438458/),[nM] / [l],96.2,138835,DB00451,Levothyroxine
,23438458,maximum plasma concentration,"For the investigative liquid preparation at a dose of 50 μg/kg, the maximum plasma concentration was 60.1 nmol/L (baseline endogenous corrected), which was reached within 3.59 h.",Bioavailability of two L-thyroxine formulations after oral administration to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438458/),[nM] / [l],60.1,138836,DB00451,Levothyroxine
,23438458,relative bioavailability,"The geometric mean of the relative bioavailability for the liquid/tablet product was 1.1, which suggests that the relative bioavailability of thyroxine following administration of tablet or liquid formulation is similar.",Bioavailability of two L-thyroxine formulations after oral administration to healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438458/),,1.1,138837,DB00451,Levothyroxine
,15553108,Cmax,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[ng] / [ml],112.0,138903,DB00451,Levothyroxine
,15553108,Cmax,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[ng] / [ml],113.4,138904,DB00451,Levothyroxine
,15553108,Cmax,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[ng] / [ml],111.3,138905,DB00451,Levothyroxine
,15553108,AUC0-24,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[h·ng] / [ml],2263.7,138906,DB00451,Levothyroxine
,15553108,AUC0-24,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[h·ng] / [ml],2307.3,138907,DB00451,Levothyroxine
,15553108,AUC0-24,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[h·ng] / [ml],2286.1,138908,DB00451,Levothyroxine
,1824339,absorption,"The model calculations of absorption (mean +/- SD for 3 of the subjects) are duodenum, 15 +/- 5%, upper jejunoileum, 29 +/- 14%, and lower jejunoileum, 24 +/- 11%.",Localization of human thyroxine absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824339/),%,15,138951,DB00451,Levothyroxine
,1824339,absorption,"The model calculations of absorption (mean +/- SD for 3 of the subjects) are duodenum, 15 +/- 5%, upper jejunoileum, 29 +/- 14%, and lower jejunoileum, 24 +/- 11%.",Localization of human thyroxine absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824339/),%,29,138952,DB00451,Levothyroxine
,1824339,absorption,"The model calculations of absorption (mean +/- SD for 3 of the subjects) are duodenum, 15 +/- 5%, upper jejunoileum, 29 +/- 14%, and lower jejunoileum, 24 +/- 11%.",Localization of human thyroxine absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824339/),%,24,138953,DB00451,Levothyroxine
,7508742,TT4,The mean basal TT4 value (9.07 +/- 0.56 and 8.90 +/- 0.73 micrograms/dl respectively) increased significantly at the first and second hours.,Comparison of the effect of a single oral L-thyroxine dose (150 micrograms) in tablet and in solution on serum thyroxine and TSH concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7508742/),[μg] / [dl],9.07,140006,DB00451,Levothyroxine
,7508742,TT4,The mean basal TT4 value (9.07 +/- 0.56 and 8.90 +/- 0.73 micrograms/dl respectively) increased significantly at the first and second hours.,Comparison of the effect of a single oral L-thyroxine dose (150 micrograms) in tablet and in solution on serum thyroxine and TSH concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7508742/),[μg] / [dl],8.90,140007,DB00451,Levothyroxine
,8794988,AUC,AUC (34.43 +/- 12.34 compared with 33.32 +/- 9.92 nmol h L-1).,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),[h·nM] / [l],34.43,140854,DB00451,Levothyroxine
,8794988,AUC,AUC (34.43 +/- 12.34 compared with 33.32 +/- 9.92 nmol h L-1).,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),[h·nM] / [l],33.32,140855,DB00451,Levothyroxine
,8794988,CLapp,CLapp (36.30 +/- 12.89 compared with 37.51 +/- 11.16 mL h-1) and half-life (7.50 +/- 1.39 compared with 6.40 +/- 0.96 h) were not significantly different in the control rats compared with the cyclophosphamide-treated rats.,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),[ml] / [h],36.30,140856,DB00451,Levothyroxine
,8794988,CLapp,CLapp (36.30 +/- 12.89 compared with 37.51 +/- 11.16 mL h-1) and half-life (7.50 +/- 1.39 compared with 6.40 +/- 0.96 h) were not significantly different in the control rats compared with the cyclophosphamide-treated rats.,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),[ml] / [h],37.51,140857,DB00451,Levothyroxine
,8794988,half-life,CLapp (36.30 +/- 12.89 compared with 37.51 +/- 11.16 mL h-1) and half-life (7.50 +/- 1.39 compared with 6.40 +/- 0.96 h) were not significantly different in the control rats compared with the cyclophosphamide-treated rats.,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),h,7.50,140858,DB00451,Levothyroxine
,8794988,half-life,CLapp (36.30 +/- 12.89 compared with 37.51 +/- 11.16 mL h-1) and half-life (7.50 +/- 1.39 compared with 6.40 +/- 0.96 h) were not significantly different in the control rats compared with the cyclophosphamide-treated rats.,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),h,6.40,140859,DB00451,Levothyroxine
,7826822,concentrations,3. Plasma lanreotide concentrations rose to 38.3 +/- 4.1 ng ml-1 2 h following injection.,"Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826822/),[ng] / [ml],38.3,143097,DB00451,Levothyroxine
,7826822,apparent plasma half-life,The apparent plasma half-life and mean residence time were 4.52 +/- 0.50 and 5.48 +/- 0.51 days respectively.,"Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826822/),d,4.52,143098,DB00451,Levothyroxine
,7826822,mean residence time,The apparent plasma half-life and mean residence time were 4.52 +/- 0.50 and 5.48 +/- 0.51 days respectively.,"Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826822/),d,5.48,143099,DB00451,Levothyroxine
,2324959,areas under the serum T4 concentration versus time curve from 0 to 8 h (AUC),"The average areas under the serum T4 concentration versus time curve from 0 to 8 h (AUC) for Synthroid, brand A, and brand B were 8.22, 6.32, and 8.70 ng-h/mL per dose (micrograms per kg body weight), respectively.",In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324959/),[ng-h] / [dose·ml],8.22,143295,DB00451,Levothyroxine
,2324959,areas under the serum T4 concentration versus time curve from 0 to 8 h (AUC),"The average areas under the serum T4 concentration versus time curve from 0 to 8 h (AUC) for Synthroid, brand A, and brand B were 8.22, 6.32, and 8.70 ng-h/mL per dose (micrograms per kg body weight), respectively.",In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324959/),[ng-h] / [dose·ml],6.32,143296,DB00451,Levothyroxine
,2324959,areas under the serum T4 concentration versus time curve from 0 to 8 h (AUC),"The average areas under the serum T4 concentration versus time curve from 0 to 8 h (AUC) for Synthroid, brand A, and brand B were 8.22, 6.32, and 8.70 ng-h/mL per dose (micrograms per kg body weight), respectively.",In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324959/),[ng-h] / [dose·ml],8.70,143297,DB00451,Levothyroxine
,2324959,peak serum concentrations (Cmax),"Respective peak serum concentrations (Cmax) for each tablet formulation were 1.26, 1.07, and 1.36 ng/mL per dose.",In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324959/),[ng] / [dose·ml],1.26,143298,DB00451,Levothyroxine
,2324959,peak serum concentrations (Cmax),"Respective peak serum concentrations (Cmax) for each tablet formulation were 1.26, 1.07, and 1.36 ng/mL per dose.",In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324959/),[ng] / [dose·ml],1.07,143299,DB00451,Levothyroxine
,2324959,peak serum concentrations (Cmax),"Respective peak serum concentrations (Cmax) for each tablet formulation were 1.26, 1.07, and 1.36 ng/mL per dose.",In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324959/),[ng] / [dose·ml],1.36,143300,DB00451,Levothyroxine
,2324959,t50%,"The corresponding dissolution rates, expressed as t50%, were 20.5, 3.06, and 14.1 min, respectively.",In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324959/),min,20.5,143301,DB00451,Levothyroxine
,2324959,t50%,"The corresponding dissolution rates, expressed as t50%, were 20.5, 3.06, and 14.1 min, respectively.",In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324959/),min,3.06,143302,DB00451,Levothyroxine
,2324959,t50%,"The corresponding dissolution rates, expressed as t50%, were 20.5, 3.06, and 14.1 min, respectively.",In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324959/),min,14.1,143303,DB00451,Levothyroxine
,12656658,basal,"In the pharmacokinetics study, basal serum concentration of Se (75+/-6 microg/l) was within the reference range (70-125 microg/l), it promptly increased at 2 h, peaked at 4 h (147+/-17 microg/l; P<0.0001) and it was abundant in serum at 24 h.",Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12656658/),[μg] / [l],75,151472,DB00451,Levothyroxine
,16079070,half-life,"Using the data from the clinical study, we estimated the half-life of perchlorate in serum at 7.5 hr and the volume of distribution at 0.34 L/kg.",Benchmark calculations for perchlorate from three human cohorts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16079070/),h,7.5,152244,DB00451,Levothyroxine
,16079070,volume of distribution,"Using the data from the clinical study, we estimated the half-life of perchlorate in serum at 7.5 hr and the volume of distribution at 0.34 L/kg.",Benchmark calculations for perchlorate from three human cohorts. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16079070/),[l] / [kg],0.34,152245,DB00451,Levothyroxine
,3371148,elimination half-time,"Although there were intraindividual variations, the mean PTU elimination half-time did not change from the hyperthyroid state (1.47 h) to the euthyroid state (1.53 h).",Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371148/),h,1.47,152955,DB00451,Levothyroxine
,3371148,elimination half-time,"Although there were intraindividual variations, the mean PTU elimination half-time did not change from the hyperthyroid state (1.47 h) to the euthyroid state (1.53 h).",Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371148/),h,1.53,152956,DB00451,Levothyroxine
,3371148,Ka,The mean Ka when hyperthyroid (2.12 h-1) was significantly increased (p less than 0.005) compared to when euthyroid (1.00 h-1).,Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371148/),1/[h],2.12,152957,DB00451,Levothyroxine
,3371148,Ka,The mean Ka when hyperthyroid (2.12 h-1) was significantly increased (p less than 0.005) compared to when euthyroid (1.00 h-1).,Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371148/),1/[h],1.00,152958,DB00451,Levothyroxine
,12065060,Biliary excretion,"4. Biliary excretion of BDE-99 was slightly greater than observed in urine, i.e. 3.6% at 72 h.","Tissue disposition, excretion and metabolism of 2,2',4,4',5-pentabromodiphenyl ether (BDE-99) in the male Sprague-Dawley rat. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065060/),%,3.6,154399,DB00451,Levothyroxine
,15277017,half-life,3. 4-OH-CB 107 had a half-life of 3.8 days; 4-OH-CB 187 had a half-life of 15 days.,Pharmacokinetics of two major hydroxylated polychlorinated biphenyl metabolites with specific retention in rat blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277017/),d,3.8,155101,DB00451,Levothyroxine
,15277017,half-life,3. 4-OH-CB 107 had a half-life of 3.8 days; 4-OH-CB 187 had a half-life of 15 days.,Pharmacokinetics of two major hydroxylated polychlorinated biphenyl metabolites with specific retention in rat blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277017/),d,15,155102,DB00451,Levothyroxine
,15277017,Volumes of distribution,"Volumes of distribution were 0.07 and 0.11 l kg(-1), respectively; clearances (ml h(-1)) were 0.67 and 0.22, respectively; and the areas under the curve were estimated as approximately 1500 and 4450 nmol h ml(-1).",Pharmacokinetics of two major hydroxylated polychlorinated biphenyl metabolites with specific retention in rat blood. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277017/),[l] / [kg],0.07,155103,DB00451,Levothyroxine
,15277017,Volumes of distribution,"Volumes of distribution were 0.07 and 0.11 l kg(-1), respectively; clearances (ml h(-1)) were 0.67 and 0.22, respectively; and the areas under the curve were estimated as approximately 1500 and 4450 nmol h ml(-1).",Pharmacokinetics of two major hydroxylated polychlorinated biphenyl metabolites with specific retention in rat blood. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277017/),[l] / [kg],0.11,155104,DB00451,Levothyroxine
,15277017,clearances,"Volumes of distribution were 0.07 and 0.11 l kg(-1), respectively; clearances (ml h(-1)) were 0.67 and 0.22, respectively; and the areas under the curve were estimated as approximately 1500 and 4450 nmol h ml(-1).",Pharmacokinetics of two major hydroxylated polychlorinated biphenyl metabolites with specific retention in rat blood. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277017/),[ml] / [h],0.67,155105,DB00451,Levothyroxine
,15277017,clearances,"Volumes of distribution were 0.07 and 0.11 l kg(-1), respectively; clearances (ml h(-1)) were 0.67 and 0.22, respectively; and the areas under the curve were estimated as approximately 1500 and 4450 nmol h ml(-1).",Pharmacokinetics of two major hydroxylated polychlorinated biphenyl metabolites with specific retention in rat blood. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277017/),[ml] / [h],0.22,155106,DB00451,Levothyroxine
,15277017,areas under the curve,"Volumes of distribution were 0.07 and 0.11 l kg(-1), respectively; clearances (ml h(-1)) were 0.67 and 0.22, respectively; and the areas under the curve were estimated as approximately 1500 and 4450 nmol h ml(-1).",Pharmacokinetics of two major hydroxylated polychlorinated biphenyl metabolites with specific retention in rat blood. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277017/),[h·nM] / [ml],1500,155107,DB00451,Levothyroxine
,15277017,areas under the curve,"Volumes of distribution were 0.07 and 0.11 l kg(-1), respectively; clearances (ml h(-1)) were 0.67 and 0.22, respectively; and the areas under the curve were estimated as approximately 1500 and 4450 nmol h ml(-1).",Pharmacokinetics of two major hydroxylated polychlorinated biphenyl metabolites with specific retention in rat blood. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277017/),[h·nM] / [ml],4450,155108,DB00451,Levothyroxine
,9099387,area under the curve,"The change in thyroid status from euthyroid to hyperthyroid caused a significant (P < 0.05), but small reduction in propranolol area under the curve (19,932 +/- 7,900 min.micrograms/L vs 15,911 +/- 1,400 min.micrograms/L) after i.v. administration.",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"19,932",158740,DB00451,Levothyroxine
,9099387,area under the curve,"The change in thyroid status from euthyroid to hyperthyroid caused a significant (P < 0.05), but small reduction in propranolol area under the curve (19,932 +/- 7,900 min.micrograms/L vs 15,911 +/- 1,400 min.micrograms/L) after i.v. administration.",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"15,911",158741,DB00451,Levothyroxine
,9099387,area under the curve,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"105,430",158742,DB00451,Levothyroxine
,9099387,area under the curve,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"226,811",158743,DB00451,Levothyroxine
,9099387,peak serum propranolol concentration,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[μg] / [l],651,158744,DB00451,Levothyroxine
,9099387,peak serum propranolol concentration,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[μg] / [l],1191,158745,DB00451,Levothyroxine
,9099387,fractional absorption,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),%,57,158746,DB00451,Levothyroxine
,9099387,fractional absorption,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),%,137,158747,DB00451,Levothyroxine
,9099387,total body clearance,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[ml] / [kg·min],58,158748,DB00451,Levothyroxine
,9099387,total body clearance,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[ml] / [kg·min],30,158749,DB00451,Levothyroxine
,9099387,arrival time,Mean arrival time after oral dosing was significantly lengthened by hyperthyroidism (100 +/- 38 minutes vs 157 +/- 71 minutes).,Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),min,100,158750,DB00451,Levothyroxine
,9099387,arrival time,Mean arrival time after oral dosing was significantly lengthened by hyperthyroidism (100 +/- 38 minutes vs 157 +/- 71 minutes).,Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),min,157,158751,DB00451,Levothyroxine
,2748253,elimination half-life,"The mean elimination half-life of T4 in 7 patients with multiple serum concentrations was 2.8 +/- 0.4 days, whereas the mean elimination half-life of triiodothyronine was 6 +/- 1.7 days.",Acute thyroxine ingestion in pediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748253/),d,2.8,159098,DB00451,Levothyroxine
,2748253,elimination half-life,"The mean elimination half-life of T4 in 7 patients with multiple serum concentrations was 2.8 +/- 0.4 days, whereas the mean elimination half-life of triiodothyronine was 6 +/- 1.7 days.",Acute thyroxine ingestion in pediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748253/),d,6,159099,DB00451,Levothyroxine
,2074718,recoveries,"The recoveries of thyroxine and 3,5,3'-triiodothyronine (T3) were 96% and 101%, respectively.",A simple method for the separation and quantitation of radiolabeled thyroid hormones in thyroxine clearance studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2074718/),%,96,161870,DB00451,Levothyroxine
,2074718,recoveries,"The recoveries of thyroxine and 3,5,3'-triiodothyronine (T3) were 96% and 101%, respectively.",A simple method for the separation and quantitation of radiolabeled thyroid hormones in thyroxine clearance studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2074718/),%,101,161871,DB00451,Levothyroxine
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],15.8,162229,DB00451,Levothyroxine
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],16.3,162230,DB00451,Levothyroxine
,11055323,time to peak plasma level,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.2,162231,DB00451,Levothyroxine
,11055323,half life,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.17,162232,DB00451,Levothyroxine
,11055323,apparent clearance,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[l] / [h],172,162233,DB00451,Levothyroxine
,11055323,apparent mean volume of distribution,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),l,540,162234,DB00451,Levothyroxine
,16965241,cumulative excretion,"The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 +/- 8.6% and 19.6 +/- 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 +/- 2.0% of dose).","Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16965241/),%,17.8,162915,DB00451,Levothyroxine
,16965241,cumulative excretion,"The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 +/- 8.6% and 19.6 +/- 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 +/- 2.0% of dose).","Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16965241/),%,19.6,162916,DB00451,Levothyroxine
,16965241,cumulative excretion,"The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 +/- 8.6% and 19.6 +/- 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 +/- 2.0% of dose).","Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16965241/),%,70.6,162917,DB00451,Levothyroxine
,2504532,AUC,The mean +/- S.D. AUC of total thyroxine after Levothroid administration (2339 +/- 404 pg.hr/mL) was slightly but significantly higher (p = 0.047) than that following Synthroid (2169 +/- 422 pg.hr/mL).,Biopharmaceutical comparison of two levothyroxine sodium products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504532/),[h·pg] / [ml],2339,163100,DB00451,Levothyroxine
,2504532,AUC,The mean +/- S.D. AUC of total thyroxine after Levothroid administration (2339 +/- 404 pg.hr/mL) was slightly but significantly higher (p = 0.047) than that following Synthroid (2169 +/- 422 pg.hr/mL).,Biopharmaceutical comparison of two levothyroxine sodium products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504532/),[h·pg] / [ml],2169,163101,DB00451,Levothyroxine
,831089,half-life,"Cortisol half-life was prolonged from 60 to 78 minutes (P less than 0.01), and metabolic clearance rate was decreased from 359 to 177 liters per day (P less than 0.001).",Cortisol secretion and metabolism in anorexia nervosa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),min,60 to 78,171705,DB00451,Levothyroxine
,831089,metabolic clearance rate,"Cortisol half-life was prolonged from 60 to 78 minutes (P less than 0.01), and metabolic clearance rate was decreased from 359 to 177 liters per day (P less than 0.001).",Cortisol secretion and metabolism in anorexia nervosa. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),[l] / [d],359 to 177,171706,DB00451,Levothyroxine
,831089,tetrahy,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,1.2,171707,DB00451,Levothyroxine
,831089,tetrahy,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,0.65,171708,DB00451,Levothyroxine
,831089,ratio,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,1.2,171709,DB00451,Levothyroxine
,831089,ratio,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,0.65,171710,DB00451,Levothyroxine
,10736287,length of hospital stay,The median length of hospital stay was 7 days.,Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),d,7,182586,DB00451,Levothyroxine
,10736287,free T(3) level,The mean free T(3) level was 316+/-67 pg/dL after then administration of a placebo.,Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),[pg] / [dl],316,182587,DB00451,Levothyroxine
,10736287,peak free T(3),"Patients who received T(3) had mean peak free T(3) levels of 972+/-88, 1351+/-299, and 1869+/-281 pg/dL for the dosages of 0.4, 0.6, and 0.8 microg/kg, respectively.",Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),[pg] / [dl],972,182588,DB00451,Levothyroxine
,10736287,peak free T(3),"Patients who received T(3) had mean peak free T(3) levels of 972+/-88, 1351+/-299, and 1869+/-281 pg/dL for the dosages of 0.4, 0.6, and 0.8 microg/kg, respectively.",Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),[pg] / [dl],1351,182589,DB00451,Levothyroxine
,10736287,peak free T(3),"Patients who received T(3) had mean peak free T(3) levels of 972+/-88, 1351+/-299, and 1869+/-281 pg/dL for the dosages of 0.4, 0.6, and 0.8 microg/kg, respectively.",Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),[pg] / [dl],1869,182590,DB00451,Levothyroxine
,10736287,half-life,The calculated half-life of T(3) was 7 hours.,Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),h,7,182591,DB00451,Levothyroxine
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],1.0,184129,DB00451,Levothyroxine
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184130,DB00451,Levothyroxine
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],10.1,184131,DB00451,Levothyroxine
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184132,DB00451,Levothyroxine
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],17.3,184133,DB00451,Levothyroxine
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184134,DB00451,Levothyroxine
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.2,184135,DB00451,Levothyroxine
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184136,DB00451,Levothyroxine
,591624,MCR,"Serum T3 concentrations decreased strikingly during starvation, from 145 +/- 7 ng/dl (mean +/- SE) to 66 +/- 9 ng/dl (P < 0.001), while the mean MCR of T3 was unchanged, with the result that T3 degradation or production rates were markedly decreased (36.4 +/- 4.5 μg/d vs. 11.2 +/- 0.7 μg/d; P < 0.001).",Effect of starvation on the production and metabolism of thyroxine and triiodothyronine in euthyroid obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/591624/),[μg] / [d],36.4,185826,DB00451,Levothyroxine
,591624,degradation,"Serum T3 concentrations decreased strikingly during starvation, from 145 +/- 7 ng/dl (mean +/- SE) to 66 +/- 9 ng/dl (P < 0.001), while the mean MCR of T3 was unchanged, with the result that T3 degradation or production rates were markedly decreased (36.4 +/- 4.5 μg/d vs. 11.2 +/- 0.7 μg/d; P < 0.001).",Effect of starvation on the production and metabolism of thyroxine and triiodothyronine in euthyroid obese patients. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/591624/),[μg] / [d],36.4,185827,DB00451,Levothyroxine
,591624,production rates,"Serum T3 concentrations decreased strikingly during starvation, from 145 +/- 7 ng/dl (mean +/- SE) to 66 +/- 9 ng/dl (P < 0.001), while the mean MCR of T3 was unchanged, with the result that T3 degradation or production rates were markedly decreased (36.4 +/- 4.5 μg/d vs. 11.2 +/- 0.7 μg/d; P < 0.001).",Effect of starvation on the production and metabolism of thyroxine and triiodothyronine in euthyroid obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/591624/),[μg] / [d],11.2,185828,DB00451,Levothyroxine
,23154888,area-under-the-concentration-time-curve from 0 to 2 h,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),[h·ng] / [ml],68.4,187627,DB00451,Levothyroxine
,23154888,area-under-the-concentration-time-curve from 0 to 2 h,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),[h·ng] / [ml],64.4,187628,DB00451,Levothyroxine
,23154888,area-under-the-concentration-time-curve from 0 to 2 h,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),[h·ng] / [ml],99.1,187629,DB00451,Levothyroxine
,23154888,area-under-the-concentration-time-curve from 0 to 48 h,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),[h·ng] / [ml],1 632,187630,DB00451,Levothyroxine
,23154888,area-under-the-concentration-time-curve from 0 to 48 h,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),[h·ng] / [ml],1 752,187631,DB00451,Levothyroxine
,23154888,area-under-the-concentration-time-curve from 0 to 48 h,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),[h·ng] / [ml],1 862,187632,DB00451,Levothyroxine
,23154888,maximum concentration,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),[ng] / [ml],67.6,187633,DB00451,Levothyroxine
,23154888,maximum concentration,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),[ng] / [ml],68.0,187634,DB00451,Levothyroxine
,23154888,maximum concentration,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),[ng] / [ml],71.4,187635,DB00451,Levothyroxine
,23154888,time of maximum concentration,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),h,2.25,187636,DB00451,Levothyroxine
,23154888,time of maximum concentration,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),h,2.38,187637,DB00451,Levothyroxine
,23154888,time of maximum concentration,"Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07.",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),h,1.96,187638,DB00451,Levothyroxine
,23154888,time to maximum concentration,"Overall rate and extent of exposure were not statistically different between formulations, but a faster onset of absorption for the solution was suggested (greater area-under-the-concentration-time-curve from 0 to 2 h and faster time to maximum concentration by an average of 30 min).",Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),min,30,187639,DB00451,Levothyroxine
,23154888,time to maximal concentration,The solution's greater early exposure and a faster time to maximal concentration of around 30 min may be of benefit to minimize drug-food interactions and deserves further investigations.,Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23154888/),min,30,187640,DB00451,Levothyroxine
,16597550,elimination half-life,Plasma pharmacokinetics were dose-linear with an elimination half-life of 2.2 h.,Safety assessment of 4'-thio-beta-D-arabinofuranosylcytosine in the beagle dog suggests a drug-induced centrally mediated effect on the hypothalamic-pituitary-adrenal axis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16597550/),h,2.2,188462,DB00451,Levothyroxine
,17259789,Cmax,"Study 1: after administration of T4-Ibsa oral solution, Cmax was 14.26+/-0.61 microg/dl, AUC0-t was 282.70 +/-14.29 microg/dl/h, Tmax was 2.71+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[μg] / [dl],14.26,188677,DB00451,Levothyroxine
,17259789,AUC0-t,"Study 1: after administration of T4-Ibsa oral solution, Cmax was 14.26+/-0.61 microg/dl, AUC0-t was 282.70 +/-14.29 microg/dl/h, Tmax was 2.71+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[μg] / [dl·h],282.70,188678,DB00451,Levothyroxine
,17259789,Tmax,"Study 1: after administration of T4-Ibsa oral solution, Cmax was 14.26+/-0.61 microg/dl, AUC0-t was 282.70 +/-14.29 microg/dl/h, Tmax was 2.71+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),h,2.71,188679,DB00451,Levothyroxine
,17259789,Cmax,"After administration of Eutirox 100 tablets, Cmax was 14.34+/-0.59 microg/dl, AUC0-t was 279.42+/-9.59 microg/dl/h and Tmax was 2.65+/-0.23 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[μg] / [dl],14.34,188680,DB00451,Levothyroxine
,17259789,AUC0-t,"After administration of Eutirox 100 tablets, Cmax was 14.34+/-0.59 microg/dl, AUC0-t was 279.42+/-9.59 microg/dl/h and Tmax was 2.65+/-0.23 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[μg] / [dl·h],279.42,188681,DB00451,Levothyroxine
,17259789,Tmax,"After administration of Eutirox 100 tablets, Cmax was 14.34+/-0.59 microg/dl, AUC0-t was 279.42+/-9.59 microg/dl/h and Tmax was 2.65+/-0.23 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),h,2.65,188682,DB00451,Levothyroxine
,17259789,Cmax,"Study 2: after administration of T3-Ibsa oral solution, Cmax was 3.19+/-0.25 ng/ml, AUC0-t was 44.79+/-2.15 ng/ml/h and Tmax was 2.31+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[ng] / [ml],3.19,188683,DB00451,Levothyroxine
,17259789,AUC0-t,"Study 2: after administration of T3-Ibsa oral solution, Cmax was 3.19+/-0.25 ng/ml, AUC0-t was 44.79+/-2.15 ng/ml/h and Tmax was 2.31+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[ng] / [h·ml],44.79,188684,DB00451,Levothyroxine
,17259789,Tmax,"Study 2: after administration of T3-Ibsa oral solution, Cmax was 3.19+/-0.25 ng/ml, AUC0-t was 44.79+/-2.15 ng/ml/h and Tmax was 2.31+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),h,2.31,188685,DB00451,Levothyroxine
,17259789,Cmax,"After administration of Ti-tre tablets, Cmax was 3.16+/-0.23 ng/ml, AUC0-t was 45.19+/-2.19 ng/ml/h and Tmax was 2.44+/-0.34 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[ng] / [ml],3.16,188686,DB00451,Levothyroxine
,17259789,AUC0-t,"After administration of Ti-tre tablets, Cmax was 3.16+/-0.23 ng/ml, AUC0-t was 45.19+/-2.19 ng/ml/h and Tmax was 2.44+/-0.34 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[ng] / [h·ml],45.19,188687,DB00451,Levothyroxine
,17259789,Tmax,"After administration of Ti-tre tablets, Cmax was 3.16+/-0.23 ng/ml, AUC0-t was 45.19+/-2.19 ng/ml/h and Tmax was 2.44+/-0.34 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),h,2.44,188688,DB00451,Levothyroxine
,6725518,peak serum radioactivity,"The peak serum radioactivity in normal subjects occurred 2 h post ingestion and was 15% and 17% of the administered dose per liter serum and 11% and 13%/liter serum in butanol-extracted serum, respectively.",L-thyroxine absorption in patients with short bowel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6725518/),%,15,207102,DB00451,Levothyroxine
,6725518,peak serum radioactivity,"The peak serum radioactivity in normal subjects occurred 2 h post ingestion and was 15% and 17% of the administered dose per liter serum and 11% and 13%/liter serum in butanol-extracted serum, respectively.",L-thyroxine absorption in patients with short bowel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6725518/),,17,207103,DB00451,Levothyroxine
,6725518,peak serum radioactivity,"The peak serum radioactivity in normal subjects occurred 2 h post ingestion and was 15% and 17% of the administered dose per liter serum and 11% and 13%/liter serum in butanol-extracted serum, respectively.",L-thyroxine absorption in patients with short bowel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6725518/),%,11,207104,DB00451,Levothyroxine
,6725518,peak serum radioactivity,"The peak serum radioactivity in normal subjects occurred 2 h post ingestion and was 15% and 17% of the administered dose per liter serum and 11% and 13%/liter serum in butanol-extracted serum, respectively.",L-thyroxine absorption in patients with short bowel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6725518/),[%] / [l],13,207105,DB00451,Levothyroxine
,29212434,oral clearance rate (CL/F),"The median oral clearance rate (CL/F), apparent volume of distribution (V/F), time to peak concentration (Tmax), and dose-normalized peak concentration (Cmax) of 13C-LT4 were estimated to be 0.712 L/h, 164.9 L, 4 h, and 7.5 ng/L/μg, respectively.","Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212434/),[l] / [h],0.712,207926,DB00451,Levothyroxine
,29212434,apparent volume of distribution (V/F),"The median oral clearance rate (CL/F), apparent volume of distribution (V/F), time to peak concentration (Tmax), and dose-normalized peak concentration (Cmax) of 13C-LT4 were estimated to be 0.712 L/h, 164.9 L, 4 h, and 7.5 ng/L/μg, respectively.","Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212434/),l,164.9,207927,DB00451,Levothyroxine
,29212434,apparent volume of distribution (V/F),"The median oral clearance rate (CL/F), apparent volume of distribution (V/F), time to peak concentration (Tmax), and dose-normalized peak concentration (Cmax) of 13C-LT4 were estimated to be 0.712 L/h, 164.9 L, 4 h, and 7.5 ng/L/μg, respectively.","Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212434/),h,4,207928,DB00451,Levothyroxine
,29212434,time to peak concentration (Tmax),"The median oral clearance rate (CL/F), apparent volume of distribution (V/F), time to peak concentration (Tmax), and dose-normalized peak concentration (Cmax) of 13C-LT4 were estimated to be 0.712 L/h, 164.9 L, 4 h, and 7.5 ng/L/μg, respectively.","Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212434/),l,164.9,207929,DB00451,Levothyroxine
,29212434,time to peak concentration (Tmax),"The median oral clearance rate (CL/F), apparent volume of distribution (V/F), time to peak concentration (Tmax), and dose-normalized peak concentration (Cmax) of 13C-LT4 were estimated to be 0.712 L/h, 164.9 L, 4 h, and 7.5 ng/L/μg, respectively.","Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212434/),h,4,207930,DB00451,Levothyroxine
,29212434,dose-normalized peak concentration (Cmax),"The median oral clearance rate (CL/F), apparent volume of distribution (V/F), time to peak concentration (Tmax), and dose-normalized peak concentration (Cmax) of 13C-LT4 were estimated to be 0.712 L/h, 164.9 L, 4 h, and 7.5 ng/L/μg, respectively.","Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212434/),[ng] / [l·μg],7.5,207931,DB00451,Levothyroxine
,29212434,dose-normalized area under the concentration-time curve from time 0 to 120 hours,"The dose-normalized area under the concentration-time curve from time 0 to 120 hours and half-life of the terminal distribution phase were 0.931 ng.h/mL/μg and 172.2 h, respectively.","Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212434/),[h·ng] / [ml·μg],0.931,207932,DB00451,Levothyroxine
,29212434,half-life of the terminal distribution phase,"The dose-normalized area under the concentration-time curve from time 0 to 120 hours and half-life of the terminal distribution phase were 0.931 ng.h/mL/μg and 172.2 h, respectively.","Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212434/),h,172.2,207933,DB00451,Levothyroxine
,8430792,production rates,kg-1 x day-1) are larger than T4 production rates (2.5 micrograms.,Thyroxine and triiodothyronine distribution and metabolism in thyroxine-replaced athyreotic dogs and normal humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430792/),μg,2.5,209029,DB00451,Levothyroxine
,8430792,production rates,"These findings suggest: 1) higher fractional transfer rates of T4 and T3 from serum to tissues and total serum T4 clearance rates in dogs than humans relate to lower canine serum T4 and T3 binding, and 2) parenteral L-T4 replacement doses required to achieve upper-normal serum total T4 concentrations in athyreotic dogs (5 micrograms.kg-1 x day-1) correspond to T4 production rates (6.8 micrograms.kg-1 x day-1).",Thyroxine and triiodothyronine distribution and metabolism in thyroxine-replaced athyreotic dogs and normal humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430792/),,6.8,209030,DB00451,Levothyroxine
,27631464,AUC,"As measures of exposure to linezolid, area under the concentration-time curve (AUC) and trough concentrations (Cmin) were calculated and compared with published therapeutic ranges (AUC 200-400 mg*h/L, Cmin 2-10 mg/L).",Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631464/),[h·mg] / [l],200-400,210037,DB00451,Levothyroxine
,27631464,Cmin,"As measures of exposure to linezolid, area under the concentration-time curve (AUC) and trough concentrations (Cmin) were calculated and compared with published therapeutic ranges (AUC 200-400 mg*h/L, Cmin 2-10 mg/L).",Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631464/),[mg] / [l],2-10,210038,DB00451,Levothyroxine
,27631464,AUC,"Drug exposure was highly variable (median, range: AUC 185, 48-618 mg*h/L, calculated Cmin 2.92, 0.0062-18.9 mg/L), and only a minority of patients had values within the target ranges (6 and 7, respectively).",Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631464/),[h·mg] / [l],185,210039,DB00451,Levothyroxine
,27631464,Cmin,"Drug exposure was highly variable (median, range: AUC 185, 48-618 mg*h/L, calculated Cmin 2.92, 0.0062-18.9 mg/L), and only a minority of patients had values within the target ranges (6 and 7, respectively).",Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631464/),[mg] / [l],2.92,210040,DB00451,Levothyroxine
,27631464,AUC,"Coadministration of inhibitors was associated with a trend to higher drug exposure, whereas 3 patients treated with levothyroxine showed exceedingly low drug exposure (AUC ∼60 mg*h/L, Cmin <0.4 mg/L).",Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631464/),[h·mg] / [l],∼60,210041,DB00451,Levothyroxine
<,27631464,Cmin,"Coadministration of inhibitors was associated with a trend to higher drug exposure, whereas 3 patients treated with levothyroxine showed exceedingly low drug exposure (AUC ∼60 mg*h/L, Cmin <0.4 mg/L).",Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631464/),[mg] / [l],0.4,210042,DB00451,Levothyroxine
,27631464,unbound fraction,The median unbound fraction in all 20 patients was 90.9%.,Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631464/),%,90.9,210043,DB00451,Levothyroxine
,19893921,AUC,"The AUC obtained after rhTSH was 4.6 times smaller than that obtained after L-T4 withdrawal (532 versus 2,423 mIU/L per day).",Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19893921/),[miu] / [d·l],532,211819,DB00451,Levothyroxine
,19893921,AUC,"The AUC obtained after rhTSH was 4.6 times smaller than that obtained after L-T4 withdrawal (532 versus 2,423 mIU/L per day).",Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19893921/),[miu] / [d·l],"2,423",211820,DB00451,Levothyroxine
,24246350,area under the curve [AUC]0-4h,"Pharmacokinetic indices showed better and faster absorption for the soft gel capsule versus tablet (area under the curve [AUC]0-4h = 16,240 vs.",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),,"16,240",214754,DB00451,Levothyroxine
,24246350,maximum absorption [Cmax],"10,960 nmol/L x 4 hours, maximum absorption [Cmax] = 108 vs. 73 nmol/L, and time of maximum absorption [Tmax] = 120 minutes vs. 180 minutes).",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),[nM] / [l],108,214755,DB00451,Levothyroxine
,24246350,maximum absorption [Cmax],"10,960 nmol/L x 4 hours, maximum absorption [Cmax] = 108 vs. 73 nmol/L, and time of maximum absorption [Tmax] = 120 minutes vs. 180 minutes).",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),[nM] / [l],73,214756,DB00451,Levothyroxine
,24246350,time of maximum absorption [Tmax],"10,960 nmol/L x 4 hours, maximum absorption [Cmax] = 108 vs. 73 nmol/L, and time of maximum absorption [Tmax] = 120 minutes vs. 180 minutes).",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),min,120,214757,DB00451,Levothyroxine
,24246350,time of maximum absorption [Tmax],"10,960 nmol/L x 4 hours, maximum absorption [Cmax] = 108 vs. 73 nmol/L, and time of maximum absorption [Tmax] = 120 minutes vs. 180 minutes).",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),min,180,214758,DB00451,Levothyroxine
,976195,Plasma half-life,"Plasma half-life was determined to be 13.6 and 19.9 min in euthyroid and chronically hypothyroid rats, respectively; it was not significantly altered from the latter during rebound (18.7 min).",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),min,13.6,225363,DB00451,Levothyroxine
,976195,Plasma half-life,"Plasma half-life was determined to be 13.6 and 19.9 min in euthyroid and chronically hypothyroid rats, respectively; it was not significantly altered from the latter during rebound (18.7 min).",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),min,19.9,225364,DB00451,Levothyroxine
,976195,Plasma half-life,"Plasma half-life was determined to be 13.6 and 19.9 min in euthyroid and chronically hypothyroid rats, respectively; it was not significantly altered from the latter during rebound (18.7 min).",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),min,18.7,225365,DB00451,Levothyroxine
,976195,secretory rates,"Calculations of theoretical TSH secretory rates prior to (50.5 +/- 4.4 mU/h) and after rebound with 20 mug T4 (25.4 +/- 4.2 mU/H) revealed that the reaccumulation of TSH in the pituitary induced with T4 cannot be attributed solely to inhibition of release, but may also involve enhancement of synthesis.",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),[mu] / [h],50.5,225366,DB00451,Levothyroxine
,976195,secretory rates,"Calculations of theoretical TSH secretory rates prior to (50.5 +/- 4.4 mU/h) and after rebound with 20 mug T4 (25.4 +/- 4.2 mU/H) revealed that the reaccumulation of TSH in the pituitary induced with T4 cannot be attributed solely to inhibition of release, but may also involve enhancement of synthesis.",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),[mu] / [h],25.4,225367,DB00451,Levothyroxine
,2170254,apparent clearance,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [h·kg],0.281,227308,DB00451,Levothyroxine
,2170254,apparent clearance,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [h·kg],0.455,227309,DB00451,Levothyroxine
,2170254,apparent volume of distribution,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [kg],0.520,227310,DB00451,Levothyroxine
,2170254,apparent volume of distribution,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [kg],1.28,227311,DB00451,Levothyroxine
,2170254,half-life,CAF half-life was lower in H(-) rats than in controls: 1.33 +/- 0.621 vs 2.12 +/- 0.676 h (-37%; P less than 0.01).,Effect of hypophysectomy on caffeine elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),h,1.33,227312,DB00451,Levothyroxine
,2170254,half-life,CAF half-life was lower in H(-) rats than in controls: 1.33 +/- 0.621 vs 2.12 +/- 0.676 h (-37%; P less than 0.01).,Effect of hypophysectomy on caffeine elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),h,2.12,227313,DB00451,Levothyroxine
,10728776,Kd,"The Kd values determined by fluorescence spectroscopy for wild type, R218H, R218P and R218M HSA binding to warfarin were 1.35, 5.38, 5.61, and 8.34 microM, respectively.",Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728776/),μM,1.35,227561,DB00451,Levothyroxine
,10728776,Kd,"The Kd values determined by fluorescence spectroscopy for wild type, R218H, R218P and R218M HSA binding to warfarin were 1.35, 5.38, 5.61, and 8.34 microM, respectively.",Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728776/),μM,5.38,227562,DB00451,Levothyroxine
,10728776,Kd,"The Kd values determined by fluorescence spectroscopy for wild type, R218H, R218P and R218M HSA binding to warfarin were 1.35, 5.38, 5.61, and 8.34 microM, respectively.",Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728776/),μM,5.61,227563,DB00451,Levothyroxine
,10728776,Kd,"The Kd values determined by fluorescence spectroscopy for wild type, R218H, R218P and R218M HSA binding to warfarin were 1.35, 5.38, 5.61, and 8.34 microM, respectively.",Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728776/),μM,8.34,227564,DB00451,Levothyroxine
,6172233,Bioavailability,Bioavailability of these drugs varies from 80 to 95%.,Clinical pharmacokinetics of antithyroid drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),%,80 to 95,231758,DB00451,Levothyroxine
,6172233,total volume of distribution,"The total volume of distribution is about 40L for methimazole and around 30L for propylthiouracil, which is about 80% protein-bound, while methimazole is virtually non-protein-bound.",Clinical pharmacokinetics of antithyroid drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),l,40,231759,DB00451,Levothyroxine
,6172233,total volume of distribution,"The total volume of distribution is about 40L for methimazole and around 30L for propylthiouracil, which is about 80% protein-bound, while methimazole is virtually non-protein-bound.",Clinical pharmacokinetics of antithyroid drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),l,30,231760,DB00451,Levothyroxine
,6172233,half-life,The half-life of methimazole is 3 to 5 hours with a total clearance of about 200ml/minute.,Clinical pharmacokinetics of antithyroid drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),h,3 to 5,231761,DB00451,Levothyroxine
,6172233,total clearance,The half-life of methimazole is 3 to 5 hours with a total clearance of about 200ml/minute.,Clinical pharmacokinetics of antithyroid drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),[ml] / [min],200,231762,DB00451,Levothyroxine
,6172233,half-life,Propylthiouracil has a half-life of 1 to 2 hours with a clearance of around 120ml/min/m2.,Clinical pharmacokinetics of antithyroid drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),h,1 to 2,231763,DB00451,Levothyroxine
,6172233,clearance,Propylthiouracil has a half-life of 1 to 2 hours with a clearance of around 120ml/min/m2.,Clinical pharmacokinetics of antithyroid drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),[ml] / [m2·min],120,231764,DB00451,Levothyroxine
above,6172233,peak therapeutic serum concentration,Preliminary dose-response studies with propylthiouracil suggest a peak therapeutic serum concentration of above 4 micrograms/ml in the treatment of thyrotoxicosis.,Clinical pharmacokinetics of antithyroid drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),[μg] / [ml],4,231765,DB00451,Levothyroxine
,1541918,serum half-life,Analysis of the clearance curves for the bolus injection suggested a single-compartment model and a serum half-life of 7.25 min.,Serum half-life and in-vivo actions of recombinant bovine placental lactogen in the dairy cow. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541918/),min,7.25,233851,DB00451,Levothyroxine
,20447070,time 0 TSH,"No difference was observed for time 0 TSH values between L-T3 and L-T4 replacement phases (1.48 +/- 0.77 vs. 1.21 +/- 0.62 mU/l, P = 0.293) at average daily doses of 40.3 +/- 11.3 mcg L-T3 and 115.2 +/- 38.5 mcg L-T4, L-T3: L-T4 ratio 0.36 +/- 0.06.","The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[mu] / [l],1.48,236545,DB00451,Levothyroxine
,20447070,time 0 TSH,"No difference was observed for time 0 TSH values between L-T3 and L-T4 replacement phases (1.48 +/- 0.77 vs. 1.21 +/- 0.62 mU/l, P = 0.293) at average daily doses of 40.3 +/- 11.3 mcg L-T3 and 115.2 +/- 38.5 mcg L-T4, L-T3: L-T4 ratio 0.36 +/- 0.06.","The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[mu] / [l],1.21,236546,DB00451,Levothyroxine
,20447070,ratio,"No difference was observed for time 0 TSH values between L-T3 and L-T4 replacement phases (1.48 +/- 0.77 vs. 1.21 +/- 0.62 mU/l, P = 0.293) at average daily doses of 40.3 +/- 11.3 mcg L-T3 and 115.2 +/- 38.5 mcg L-T4, L-T3: L-T4 ratio 0.36 +/- 0.06.","The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),,0.36,236547,DB00451,Levothyroxine
,20447070,AUC(0-60),TRH stimulation test resulted in similar L-T3 vs. L-T4 TSH responses with AUC(0-60) of 326.1 (95% CI 232.6-457.1) and 247.1 (95% CI 153.8-397.1) mU* min/l (P = 0.285); and C(max) of 6.83 (95% CI 4.88-9.55) and 5.23 (95% CI 3.31-8.3) mU/l (P = 0.383).,"The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[min·mu] / [l],326.1,236548,DB00451,Levothyroxine
,20447070,AUC(0-60),TRH stimulation test resulted in similar L-T3 vs. L-T4 TSH responses with AUC(0-60) of 326.1 (95% CI 232.6-457.1) and 247.1 (95% CI 153.8-397.1) mU* min/l (P = 0.285); and C(max) of 6.83 (95% CI 4.88-9.55) and 5.23 (95% CI 3.31-8.3) mU/l (P = 0.383).,"The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[min·mu] / [l],247.1,236549,DB00451,Levothyroxine
,20447070,C(max),TRH stimulation test resulted in similar L-T3 vs. L-T4 TSH responses with AUC(0-60) of 326.1 (95% CI 232.6-457.1) and 247.1 (95% CI 153.8-397.1) mU* min/l (P = 0.285); and C(max) of 6.83 (95% CI 4.88-9.55) and 5.23 (95% CI 3.31-8.3) mU/l (P = 0.383).,"The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[mu] / [l],6.83,236550,DB00451,Levothyroxine
,20447070,C(max),TRH stimulation test resulted in similar L-T3 vs. L-T4 TSH responses with AUC(0-60) of 326.1 (95% CI 232.6-457.1) and 247.1 (95% CI 153.8-397.1) mU* min/l (P = 0.285); and C(max) of 6.83 (95% CI 4.88-9.55) and 5.23 (95% CI 3.31-8.3) mU/l (P = 0.383).,"The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[mu] / [l],5.23,236551,DB00451,Levothyroxine
,28898054,T1/2,"The entities were functionalized with a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator via a l-lysine and β-alanine linker moiety using solid-phase peptide chemistry and labeled with 177Lu (T1/2 = 6.65 days), a clinically established radiometal.","Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28898054/),d,6.65,241701,DB00451,Levothyroxine
,28898054,"T1/2,β","177Lu-DOTA-PPB-01 showed the slowest blood clearance (T1/2,β: >15 h) followed by 177Lu-DOTA-PPB-03 (T1/2,β: ∼2.33 h) and 177Lu-DOTA-PPB-02 (T1/2,β: ∼1.14 h), which was excreted relatively fast.","Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28898054/),h,∼2.33,241702,DB00451,Levothyroxine
,31227723,Cmax,"Pharmacokinetic studies using LC-MS/MS analysis in male C57BL/6 mice showed that administration of NDAT improved the area under the drug concentration curve AUC(0-48 h) by 4-fold at a dose of 3 mg/kg when compared with DAT, and Cmax of NDAT (4363 ng/mL) was 8-fold greater than that of DAT (548 ng/mL).","Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31227723/),[ng] / [ml],4363,243183,DB00451,Levothyroxine
,31227723,Cmax,"Pharmacokinetic studies using LC-MS/MS analysis in male C57BL/6 mice showed that administration of NDAT improved the area under the drug concentration curve AUC(0-48 h) by 4-fold at a dose of 3 mg/kg when compared with DAT, and Cmax of NDAT (4363 ng/mL) was 8-fold greater than that of DAT (548 ng/mL).","Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31227723/),[ng] / [ml],548,243184,DB00451,Levothyroxine
,11716045,maximum,"When 1,000 microg of levothyroxine alone was given to subjects, the maximum average total T4 absorption was 837 microg (83.7% of the dose ingested) at 120 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,837,245768,DB00451,Levothyroxine
,11716045,total T4 absorption,"When 1,000 microg of levothyroxine alone was given to subjects, the maximum average total T4 absorption was 837 microg (83.7% of the dose ingested) at 120 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,837,245769,DB00451,Levothyroxine
,11716045,maximum,"When levothyroxine was coadministered with 2.0 g of calcium (as calcium carbonate), the maximum average T4 absorption decreased to 579 microg (57.9% of the dose ingested) at 240 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,579,245770,DB00451,Levothyroxine
,11716045,T4 absorption,"When levothyroxine was coadministered with 2.0 g of calcium (as calcium carbonate), the maximum average T4 absorption decreased to 579 microg (57.9% of the dose ingested) at 240 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,579,245771,DB00451,Levothyroxine
,4090911,bioavailability,"The bioavailability of T4 in 6 euthyroid controls was in median 65% (range 64-75%), and it was significantly increased both in hyperthyroidism (88% (75-99%), n = 6, P less than 0.01) and hypothyroidism (84% (67-100%), n = 6, P less than 0.02).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,65,246121,DB00451,Levothyroxine
,4090911,bioavailability,"The bioavailability of T4 in 6 euthyroid controls was in median 65% (range 64-75%), and it was significantly increased both in hyperthyroidism (88% (75-99%), n = 6, P less than 0.01) and hypothyroidism (84% (67-100%), n = 6, P less than 0.02).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,88,246122,DB00451,Levothyroxine
,4090911,bioavailability,"The bioavailability of T4 in 6 euthyroid controls was in median 65% (range 64-75%), and it was significantly increased both in hyperthyroidism (88% (75-99%), n = 6, P less than 0.01) and hypothyroidism (84% (67-100%), n = 6, P less than 0.02).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,84,246123,DB00451,Levothyroxine
,4090911,bioavailability,The bioavailability of T3 in 6 euthyroid controls was in median 78% (69-99%) and significantly greater than that of T4 (P less than 0.02).,"The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,78,246124,DB00451,Levothyroxine
,4090911,bioavailability,"The bioavailability was unaffected by hyperthyroidism (79% (61-98%), n = 9) and hypothyroidism (77% (66-97%), n = 7).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,79,246125,DB00451,Levothyroxine
,4090911,bioavailability,"The bioavailability was unaffected by hyperthyroidism (79% (61-98%), n = 9) and hypothyroidism (77% (66-97%), n = 7).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,77,246126,DB00451,Levothyroxine
,4090911,bioavailability,The clinical implication of the present study is that the bioavailability of T4 and T3 is almost identical and approximately 80% in patients with severe hypothyroidism.,"The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,80,246127,DB00451,Levothyroxine
,3428340,kel,"Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively).",Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428340/),1/[h],0.155,253177,DB00451,Levothyroxine
,3428340,kel,"Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively).",Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428340/),1/[h],0.060,253178,DB00451,Levothyroxine
,3428340,kel,"Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively).",Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428340/),1/[h],0.107,253179,DB00451,Levothyroxine
,6806535,metabolic clearance rates,"The metabolic clearance rates and production rates for thyroxine were 21.5 +/- 0.6 ml/kg/day and 1.34 +/- 0.23 micrograms/kg/day, respectively, and T1/2(beta) = 29.6 +/- 2.0 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),[ml] / [d·kg],21.5,253484,DB00451,Levothyroxine
,6806535,production rates,"The metabolic clearance rates and production rates for thyroxine were 21.5 +/- 0.6 ml/kg/day and 1.34 +/- 0.23 micrograms/kg/day, respectively, and T1/2(beta) = 29.6 +/- 2.0 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),[μg] / [d·kg],1.34,253485,DB00451,Levothyroxine
,6806535,T1/2(beta),"The metabolic clearance rates and production rates for thyroxine were 21.5 +/- 0.6 ml/kg/day and 1.34 +/- 0.23 micrograms/kg/day, respectively, and T1/2(beta) = 29.6 +/- 2.0 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),h,29.6,253486,DB00451,Levothyroxine
,6806535,metabolic clearance rate,"For triiodothyronine, the metabolic clearance rate was 156.6 +/- 12.0 ml/kg/day, the production rate was 0.33 +/- 0.04 micrograms/kg/day, and T1/2 (beta) was 13.3 +/- 1.3 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),[ml] / [d·kg],156.6,253487,DB00451,Levothyroxine
,6806535,production rate,"For triiodothyronine, the metabolic clearance rate was 156.6 +/- 12.0 ml/kg/day, the production rate was 0.33 +/- 0.04 micrograms/kg/day, and T1/2 (beta) was 13.3 +/- 1.3 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),[μg] / [d·kg],0.33,253488,DB00451,Levothyroxine
,6806535,T1/2 (beta),"For triiodothyronine, the metabolic clearance rate was 156.6 +/- 12.0 ml/kg/day, the production rate was 0.33 +/- 0.04 micrograms/kg/day, and T1/2 (beta) was 13.3 +/- 1.3 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),h,13.3,253489,DB00451,Levothyroxine
,7122691,plasma half-life,The plasma half-life after the first dose averaged 0.66 h and became greater than 1 h with chronic drug therapy.,Propylthiouracil disposition in pregnant and post-partum women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122691/),h,0.66,255004,DB00451,Levothyroxine
greater,7122691,plasma half-life,The plasma half-life after the first dose averaged 0.66 h and became greater than 1 h with chronic drug therapy.,Propylthiouracil disposition in pregnant and post-partum women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122691/),h,1,255005,DB00451,Levothyroxine
,7122691,apparent volume of distribution,"The apparent volume of distribution after the first dose averaged 0.26 liter/kg, similar to nonpregnant hyperthyroid patients.",Propylthiouracil disposition in pregnant and post-partum women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122691/),[l] / [kg],0.26,255006,DB00451,Levothyroxine
,6489432,half-life,In hyperthyroidism the half-life of antipyrine was significantly shorter (p less than 0.05) than after recovery (9.3 +/- 1.0 versus 10.6 +/- 0.9 h).,Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),h,9.3,258926,DB00451,Levothyroxine
,6489432,half-life,In hyperthyroidism the half-life of antipyrine was significantly shorter (p less than 0.05) than after recovery (9.3 +/- 1.0 versus 10.6 +/- 0.9 h).,Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),h,10.6,258927,DB00451,Levothyroxine
,6489432,elimination half-life,Hypothyroid patients showed a significantly longer elimination half-life before treatment than after recovery (12.7 +/- 2.6 versus 10.3 +/- 2.6 h).,Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),h,12.7,258928,DB00451,Levothyroxine
,6489432,elimination half-life,Hypothyroid patients showed a significantly longer elimination half-life before treatment than after recovery (12.7 +/- 2.6 versus 10.3 +/- 2.6 h).,Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),h,10.3,258929,DB00451,Levothyroxine
,6489432,clearance,"Antipyrine clearance in hyperthyroid patients was decreased after treatment from 2.7 +/- 0.3 to 2.4 +/- 0.3 l/h, and it was increased in hypothyroid patients from 2.1 +/- 0.4 to 2.5 +/- 0.5 l/h (p less than 0.05).",Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),[l] / [h],2.7,258930,DB00451,Levothyroxine
,6489432,clearance,"Antipyrine clearance in hyperthyroid patients was decreased after treatment from 2.7 +/- 0.3 to 2.4 +/- 0.3 l/h, and it was increased in hypothyroid patients from 2.1 +/- 0.4 to 2.5 +/- 0.5 l/h (p less than 0.05).",Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),[l] / [h],2.4,258931,DB00451,Levothyroxine
,6489432,clearance,"Antipyrine clearance in hyperthyroid patients was decreased after treatment from 2.7 +/- 0.3 to 2.4 +/- 0.3 l/h, and it was increased in hypothyroid patients from 2.1 +/- 0.4 to 2.5 +/- 0.5 l/h (p less than 0.05).",Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),[l] / [h],2.1,258932,DB00451,Levothyroxine
,6489432,clearance,"Antipyrine clearance in hyperthyroid patients was decreased after treatment from 2.7 +/- 0.3 to 2.4 +/- 0.3 l/h, and it was increased in hypothyroid patients from 2.1 +/- 0.4 to 2.5 +/- 0.5 l/h (p less than 0.05).",Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),[l] / [h],2.5,258933,DB00451,Levothyroxine
<,16045952,fT4,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],2,262136,DB00451,Levothyroxine
<,16045952,fT3,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],1,262137,DB00451,Levothyroxine
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],3360,262138,DB00451,Levothyroxine
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],215,262139,DB00451,Levothyroxine
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],4040,262140,DB00451,Levothyroxine
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],724,262141,DB00451,Levothyroxine
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],248,262142,DB00451,Levothyroxine
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],528,262143,DB00451,Levothyroxine
,2865201,T4,Thyroid hormone injections significantly increased T4 levels (182.8 nM +/- 11.6 (SEM) versus 50.2 +/- 6.4; P less than 0.001) and baseline glucose concentrations (9.3 mM +/- 0.2 versus 7.1 +/- 0.2; P less than 0.001).,Insulin secretion and action in the hyperthyroid rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865201/),nM,182.8,270654,DB00451,Levothyroxine
,2865201,T4,Thyroid hormone injections significantly increased T4 levels (182.8 nM +/- 11.6 (SEM) versus 50.2 +/- 6.4; P less than 0.001) and baseline glucose concentrations (9.3 mM +/- 0.2 versus 7.1 +/- 0.2; P less than 0.001).,Insulin secretion and action in the hyperthyroid rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865201/),nM,50.2,270655,DB00451,Levothyroxine
,2865201,metabolic clearance rate of,The metabolic clearance rate of insulin (ml/min/kg +/- SEM) was significantly (P less than 0.01) increased (54.4 +/- 3.5 versus 41.6 +/- 2.3) in the hyperthyroid rats.,Insulin secretion and action in the hyperthyroid rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865201/),[ml] / [kg·min],54.4,270656,DB00451,Levothyroxine
,2865201,metabolic clearance rate of,The metabolic clearance rate of insulin (ml/min/kg +/- SEM) was significantly (P less than 0.01) increased (54.4 +/- 3.5 versus 41.6 +/- 2.3) in the hyperthyroid rats.,Insulin secretion and action in the hyperthyroid rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865201/),[ml] / [kg·min],41.6,270657,DB00451,Levothyroxine
